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Abstract 
Breast cancer is the most common female cancer worldwide. This thesis aims to 
evaluate the cost-effectiveness of breast cancer control across different healthcare 
contexts and estimate the costs of breast cancer treatment. Four case studies are 
presented providing detailed estimates of the cost-effectiveness of risk-based breast 
screening in urban China, the cost-effectiveness of population-based breast screening 
in rural China, the cost-effectiveness of panel genetic testing among unselected breast 
cancer patients in the UK and US, and cost of breast cancer treatment by stage at 
diagnosis in England.  
The economic evaluation studies on breast cancer screening show that in urban China, 
high-risk population-based screening for breast cancer is very likely to be cost-effective. 
But in rural China, breast screening among the general population reports uncertain cost-
effectiveness and could potentially harm women’s health due to false positives with the 
current screening tools. In a rural setting with such low breast cancer incidence, priority 
should be given to ensure that symptomatic women have proper access to diagnosis 
and treatment at an early stage as this will lead to mortality reductions without the usual 
screening harms. 
The economic evaluation on genetic testing based on a microsimulation model showed 
that unselected panel genetic-testing for all breast cancer patients is extremely cost-
effective compared to the current practice of family-history/clinical-criteria based genetic 
(BRCA)-testing for both UK and US health systems. This supports changing the current 
policy to expand genetic-testing to all women with breast cancer.   
Costs of breast cancer care increased with increasing stage of the disease at diagnosis 
in England. Considerable cost savings could be made if breast cancer was detected and 
treated earlier. Variations in breast cancer costs by age andregion raise questions about 
the efficiency and consistency of breast cancer treatment patterns. Future research could 
be conducted by undertaking multiple imputation for missing data and censored-adjusted 
analysis.  
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Chapter 1 Introduction  
1.1 Introduction to this thesis 
Breast cancer is the most common cancer among women worldwide. The aim of this 
thesis is to evaluate the cost-effectiveness of breast cancer control across different 
healthcare contexts and estimate the costs of breast cancer treatments. I present four 
empirical case studies in this thesis, including the cost-effectiveness of risk-based breast 
screening in urban China, the cost-effectiveness of population-based breast screening 
in rural China, the cost-effectiveness of panel genetic testing among unselected breast 
cancer patients in the UK and US, and cost of breast cancer treatment by stage at 
diagnosis in England. 
Breast cancer screening is the key to breast cancer control. Numerous economic 
evaluations have been published that explore the cost-effectiveness of breast cancer 
screening in low- and middle-income countries (LMICs) (1-15), but the evidence on the 
breast cancer screening programme in China is insufficient. In China, two pilot breast 
cancer screening programmes have been conducted in urban and rural areas 
respectively. Chinese urban women at high risk aged 40-69 years were screened by 
ultrasound and/followed by mammography (16), and rural women at average risk aged 
35-64 years were screened by clinical breast examination coupled with ultrasound as 
the primary tool (17). However, the relevant economic evidence on the two pilot breast 
cancer screening programmes in China is still lacking. In this thesis, two of the case 
studies are presented on the economic evaluation of breast cancer screening in the pilot 
programmes in urban and rural China respectively.  
Breast cancer genetic testing has been increasingly conducted in high-income countries 
(HIC) over the past few years (18-21). Current national and international guidelines 
recommend genetic testing in breast cancer patients only if they have a 10% risk of 
being a BRCA carrier based on family history and clinical criteria (22, 23). However, 
breast cancer patients with gene mutations do not always have a positive family history 
and these criteria can miss a large proportion (~50%) of mutation carriers (21, 24, 25). 
For breast cancer patients, mutation identification enables primary prevention of 
contralateral breast cancer and ovarian cancer. For the relatives of breast cancer 
mutation carriers, mutation identification provides the opportunity for early diagnosis and 
prevention of breast cancer and ovarian cancer. In the third case study, I used data from 
four large clinical trials/research cohorts to evaluate the cost-effectiveness of offering 
unselected panel genetic testing to all breast cancer patients compared to the current 
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practice of restricting genetic testing for breast cancer patients based on family history 
and clinical criteria in the UK and US settings.  
In addition to economic evaluations of breast cancer control based on modelling, I 
analysed the treatment costs of breast cancer care based on patient-level data. UK data 
on the costs of breast cancer treatment by stage at diagnosis are out-of-date and were 
published over 20 years ago (26). Recent NICE appraisals on the cost-effectiveness of 
breast cancer treatments have instead relied on modelled assumptions (27). Up-to-date 
estimates of the costs of breast cancer treatments by stage are thus required. In the 
fourth case study, I used patient-level data from women aged 50 years and over 
diagnosed with early invasive breast cancer in England to estimate the costs of breast 
cancer care by stage at diagnosis, and explore to what extent the breast cancer costs 
vary across different patient groups and regions. 
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1.2 Research aim and objectives 
1.2.1 Aim 
To evaluate the cost-effectiveness of breast cancer control across different healthcare 
contexts and estimate the costs of breast cancer treatment.   
1.2.2 Research objectives 
• To review the literature on economic evaluations of breast cancer screening in 
LMICs and breast cancer genetic testing in HICs 
• To evaluate the cost-effectiveness of breast cancer screening in the pilot 
programmes in urban and rural China compared to no screening  
• To evaluate the cost-effectiveness of offering multi-gene testing to all breast 
cancer patients compared to the current practice of family-history/clinical-criteria 
based genetic testing in the UK and the US 
• To review the literature on treatment costs of breast cancer by stage across all 
countries and identify the methodological differences in costing approaches 
• To analyse the treatment costs of breast cancer by stage at diagnosis using 
patient-level data in England 
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1.3 Thesis structure 
This thesis is structured as follows.  
• Chapter 2 provides an overview of economic evaluation methods, an overview 
of costing analysis methods, and background information on breast cancer 
screening, genetic testing, and treatment. 
• Chapter 3 reviews the literature on breast cancer control modelling, including 
economic evaluation of breast cancer screening in low- and middle-income 
countries, and economic evaluation of breast cancer genetic testing in high-
income countries.  
• Chapter 4 evaluates the cost-effectiveness of risk-based breast cancer 
screening programmes in urban China based on a Markov model. 
• Chapter 5 evaluates the cost-effectiveness of population-based breast cancer 
screening programmes in rural China based on a Markov model. 
• Chapter 6 evaluates the cost-effectiveness of offering panel genetic testing to 
all breast cancer patients compared to the current practice of genetic testing for 
breast cancer patients based on family history/clinical-criteria using a 
microsimulation model. 
• Chapter 7 reviews the literature on treatment costs of breast cancer globally 
and compare the methodological differences in costing approaches.  
• Chapter 8 analyses the costs of care among women aged 50 years and over 
with a histological diagnosis of early invasive breast cancer in England. 
• Chapter 9 reviews the key findings, discusses the policy and practice 
implications, reflects on the methodology for modelling, and discusses the 
limitations. The areas of future research are also discussed. 
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Chapter 2 Background 
The aims of this Chapter are: (i) to give an overview of economic evaluation methods; (ii) 
to give an overview of costing analysis methods; (iii) to provide a background to breast 
cancer screening, genetic testing, and treatment. 
2.1 Overview of Economic Evaluation 
The objective of this section is to provide an overview of economic evaluation methods 
including the rationale, approaches, and uncertainty.  
2.1.1 Economic evaluation rationale 
Economic evaluation of health interventions is defined as “the comparative analysis of 
alternative courses of action in terms of their costs and consequences” (28). The main 
types of economic evaluation include cost-effectiveness analysis, cost-utility analysis, 
cost-benefit analysis, and cost-minimisation analysis. Cost-benefit analysis is very rarely 
conducted in the context of health care as all health benefits are measured in monetary 
terms. Cost-minimisation analysis should only be used where there is strong evidence 
that health outcomes are equivalent.  
Cost-effectiveness analysis 
In cost-effectiveness analysis, effects are measured in natural units which can be either 
intermediate outcomes (e.g. cases detected, change in mortality) or final outcomes (e.g. 
life years gained). Cost-effectiveness analysis can be easily performed but it has very 
limited scope of comparability because it is difficult to compare alternatives with different 
outcome measures (29).  
Cost-utility analysis 
Cost-utility analysis uses quality-adjusted life years (QALYs) or disability-adjusted life 
years (DALYs) to measure health consequences (29). QALY and DALY are generic 
health outcomes and therefore can be compared across disease areas and interventions. 
QALYs are estimated by weighting time spent in the relevant health states by the health-
related quality of life, with both morbidity and mortality taken into account. DALYs are 
used to calculate the years of life lost from illness and years lived with a disability. The 
advantage of cost-utility analysis is that the health outcomes are measured with the same 
units. Therefore, it can be used to compare results in different health areas. Sometimes 
the term ‘cost-utility analysis’ can be used interchangeably with the term ‘cost-
effectiveness analysis’. In the UK, US, and China settings, cost-utility analysis is primarily 
recommended with QALYs considered to be the most appropriate generic measure of 
health outcomes (30-32). 
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Decision rules in economic evaluation 
Economic evaluation is the comparative analysis of alternative interventions in terms of 
costs and health effects. When comparing a new intervention to a current comparator, 
four scenarios could arise which can be represented on a cost-effectiveness plane in 
Figure 2-1 (33).  
 
Figure 2-1 Cost-effectiveness plane 
The horizontal axis reflects the difference in effects between the new intervention and 
the comparator, and the vertical axis the difference between costs of the new intervention 
relative to the comparator. In the north-west quadrant, the new intervention is more costly 
and less effective, so the comparator dominates the intervention. In the south-east 
quadrant, the new intervention is cheaper and more effective, so the intervention 
dominates the comparator. In the north-east quadrant, the new intervention is more 
effective but also costlier. This scenario is the most commonly encountered in economic 
evaluation. Also in the south-west quadrant, the new intervention is cheaper but less 
effective so there is no clear dominating intervention.  
The traditional statistic of interest from an economic evaluation is the incremental cost-
effectiveness ratio (ICER), which is derived by dividing the difference in intervention and 
comparator costs by the corresponding difference in effects between the comparators, 
as below:  
ICER= (Cost Strategy-A – Cost Strategy-B) / (Effect Strategy-A – Effect Strategy-B) 
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To understand whether the resultant ICER represents good value for money, it needs to 
be compared with the willingness to pay (WTP) threshold, which indicates the amount 
that the decision makers are willing to pay for an additional unit of health benefit. If the 
ICER is lower than WTP threshold (intervention falling below the threshold), the 
intervention is cost-effective and could be adopted. This is because the net gain in health 
from the allocation of resources is said to be positive. 
In the UK, the National Institute for Health and Care Excellence (NICE) provides the 
current threshold guideline (30). Broadly speaking, it suggests that interventions with 
good evidence that an ICER is lower than £20,000/QALY should be accepted. Between 
£20,000/QALY and £30,000/QALY, other reasons than cost-effectiveness are required, 
for example equity considerations, and above £30,000/QALY interventions should not 
be adopted (30). In the US, the $50,000/QALY to $100,000/QALY amount is often cited 
in the literature as the cost-effectiveness threshold: interventions that produce a QALY 
for $50,000 or less are good value for money, where those that require $100,000 or more 
are not (34). Whilst there is no recommended threshold in China, the World Health 
Organisation suggested that three times Gross Domestic Product (GDP) per capita as 
the threshold of being cost-effective and one time GDP per-capita as the threshold of 
being highly cost-effective (35). Therefore, in this thesis I used the thresholds of 
£20,000/QALY-£30,000/QALY (UK analysis), $50,000/QALY-$100,000/QALY (US 
analysis), and $23,050/QALY (36) (China analysis, three times GDP per capita). The 
choice of cost-effectiveness thresholds is discussed in Chapter 9.  
2.1.2 Economic evaluation approaches 
Clinical trials/cohort studies and decision models are two dominant approaches to 
conducting economic evaluations.   
Clinical trials/cohort studies occupy an important role in evaluating health interventions 
(37). Economic evaluations conducted alongside pragmatic trials or cohorts provide an 
opportunity to collect costs and health effects prospectively. Also, this provides access 
to data on individual patients so sampling uncertainty can be captured (38). In addition, 
costs and outcomes are correlated because data are collected from the same settings.  
A key concern about clinical trials and cohort studies is the limited follow-up periods 
where events can happen beyond follow-up periods, while decision models are 
potentially able to predict both short-time and lifetime cost-effectiveness. However, these 
predictions are conditional on the models being correct. Secondly, few clinical trials or 
cohort studies will include more than two options and therefore it is hard to compare 
multiple comparators. Thirdly, single studies often fail to collect all the data necessary 
 21 
for economic evaluation, such as resource use and health-related quality of life. Some 
evidence needs to be obtained from other studies to help inform decision-making (37).  
A decision model is a mathematical structure that represents a disease process with 
probabilities of health events occurring. Decision models for economic evaluations are 
subject to some limitations such as combining heterogeneous pieces of information and 
adopting modelling assumptions. Different types of decision models and methods by 
which they are run, exist, such as decision trees, Markov models, and microsimulation 
models.  
Decision trees 
Decision trees are the simplest form of decision model where health events are modelled 
by a series of nodes and branches. Decision trees are only used to solve simple 
problems because it assumes events occur instantaneously and is not efficient for events 
that occur repeatedly such as cancer screening.  
Markov models 
Markov models currently dominate the healthcare economic evaluation literature (39). It 
is an analytical structure characterised by the Markov assumption of memorylessness, 
whereby the transition probabilities are independent of the nature or timing of earlier 
transitions (39). Discrete-time Markov model has an explicit time horizon which is 
separated into fixed time cycles. Individuals in the cohort are in one of the finite set of 
health states that reflect the disease progression, and they transition between states 
according to the transition probabilities over the time horizon.  
Microsimulation models 
Microsimulation is an individual-based model that follows the progress of individuals with 
specific attributes over time (40). It permits individual heterogeneity when patient 
characteristics impact the pathways through the model. Also, it could track individual 
patient history if the memory of events impacts future cycles. Individual-based models 
are more flexible and adopt less stringent assumptions compared to cohort models, but 
require more data and are typically more computationally expensive. For example, in 
Chapter 6 the microsimulation model required data on characteristics relating to each 
genetic mutation type. 
In this thesis I used Markov models in Chapter 4 and Chapter 5 to estimate the lifetime 
costs and health effects of breast cancer screening. Also the individuals in the cohorts 
had the same start age and were screened with the same tools. Therefore, Markov 
models were the most appropriate in these analyses. In Chapter 6,  individuals were 
different in age and gene types. The individual history of undertaking different risk-
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reducing options needs to be tracked as this would impact their disease transition 
probabilities in future cycles. So microsimulation modelling was used in Chapter 6.  
2.1.3 Uncertainty in economic evaluation 
In addition to the point estimate of ICER, uncertainty information is required to inform 
decision-making.  
Parameter uncertainty 
The uncertainty of model parameter exists due to the sampling errors and the synthesis 
of data from different sources (41). 
Parameter sensitivity analysis includes deterministic sensitivity analysis (DSA) and 
probabilistic sensitivity analysis (PSA). DSA varies individual parameters (one-way 
sensitivity analysis) or a few parameters individually (multi-way sensitivity analysis) to 
observe their effect on the ICERs. PSA could interpret the joint effect of uncertainty 
across multiple variables simultaneously. In PSA, the input variables are defined as 
random variables. Costs are normally specified as having a Gamma distribution, quality 
of life as having a Log-normal distribution, and probability as having a Beta distribution, 
as suggested in the literature (42). The incremental net monetary benefit (INMB) is a 
summary statistic that represents the value of an intervention in monetary terms when a 
WTP threshold is known. The use of INMB scales both health outcomes and resource 
use to costs, which allows the comparison of results without using the traditional ICER 
thus avoiding the problems of interpreting a negative ICER (43). INMB is defined as (44): 
INMB= λ * (Effect Strategy-A – Effect Strategy-B) - (Cost Strategy-A – Cost Strategy-B) 
Where λ is the WTP threshold. If INMB>0, the new intervention is cost-effective because 
the cost to derive the health benefit is less than the maximum amount that the decision-
maker would be willing to pay for this benefit. For PSA, a large number of estimates of 
incremental costs and effects can be obtained by sampling from the distributions and the 
widespread convention in current practice is to conduct between 1,000 and 10,000 
simulations (45). Then a cost-effectiveness acceptability curve (CEACs) could be plotted 
to show the probability of the intervention being cost-effective at different levels of WTP 
thresholds.  
Other forms of uncertainty 
There are other forms of uncertainty in economic evaluation, including model structure 
uncertainty (uncertainty about assumptions that underlie decision models), 
methodological uncertainty (uncertainty regarding the scope of analysis), heterogeneity 
uncertainty (variation between patients with particular characteristics), and 
generalisability uncertainty (uncertainty about whether the results apply in different 
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contexts). The uncertainty can be reduced by improved analysis (e.g. scenario analysis) 
with more information or clarity regarding decision-makers objective function.  
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2.2 Overview of costing analysis 
The objective of this section is to provide an overview of cost data collection, perspective, 
and statistical analysis.  
2.2.1 Cost data collection 
There are two main approaches to collecting cost data. One approach is micro-costing, 
also called the bottom-up method, which entails the direct measurement of resource use 
and the associated unit costs at the micro-level. The other approach is gross costing or 
top-down method. In gross costing, health services or healthcare interventions are 
broken down into large components and these large cost items have to be identified (46, 
47). Gross costing is faster and cheaper but may lead to low accuracy because of the 
relatively large measurement units. Micro-costing is more reliable but may be expensive 
and not always practical (47). Costing data collection methods should depend on the aim 
of the study and the availability of data (47). 
2.2.2 Perspective 
The main perspectives for economic evaluations and costing studies are societal 
perspective and payer perspective. From a societal perspective, all costs (direct medical 
costs, direct non-medical costs, and indirect costs) are taken into account. Direct medical 
costs are the expenditures on direct purchasing of inpatient and outpatient medical 
services, such as diagnostic fees, drug fees, etc. Direct non-medical costs are 
expenditures as the result of an illness but not involved in the direct purchasing of 
medical services, such as travel and lodging. Indirect costs are the lost earnings due to 
the productivity loss related to the morbidity and mortality of illness (48), including 
temporary disability due to short-term work absences following diagnosis, permanent 
disability due to reduced working hours following a return to work or workforce departure, 
and premature mortality due to death before retirement (49).  
From a healthcare system/payer perspective, health care providers are only concerned 
about the direct medical costs falling on their institutions irrespective of any wider 
implication (50). A payer perspective may provide evidence to allocate resources within 
the limited budget, but not necessarily maximize the welfare of the whole society (51). 
The UK recommends a payer perspective for the primary analysis (30), while in China a 
societal perspective is primarily recommended (32). In the US, all cost-effectiveness 
analyses should report two reference case analyses: one based on a payer perspective 
and the other based on a societal perspective (52). In this thesis, I adopt a societal 
perspective in the two case studies of economic evaluation in China, both payer and 
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societal perspectives in the case study of economic evaluation in the UK and US, and a 
payer perspective in the case study of costing analysis in England.  
2.2.3 Statistical analysis 
Cost data have some statistical issues, including skewness, zero costs, and censoring.  
Skewness 
Skewness is a measure of the asymmetry of the distribution of a variable, which can be 
positive or negative or zero. Positive skewness indicates that the tail on the right side of 
the distribution is longer than the left side and the main part of the values (including the 
median) lie to the left of the mean (53). The distribution of cost data is almost always 
right-skewed due to a minority of patients with very high medical costs (47). In this case, 
some argued that median can be an alternative to mean as the response to the violation 
of normality, representing the measure of central tendency better (54, 55). However, 
costs are usually added together to build up the total expenditure, thus mean is a more 
meaningful measure than median for decision makers (56).   
Zero values 
Zero-costs indicate that according to the definition of cost adopted in the study (for 
example hospitalization costs), no actual costs have been recorded for that patient (e.g. 
because no hospitalizations occurred) and thus to the cost variable is given a value of 
zero. A possible large mass of zero observations (true zeroes, not censored values) can 
cause problems to the application of standard methods. It could also be highly 
questionable that the two populations, one with zero and the other with positive costs, 
have the same behaviour with respect to the covariates (53). 
Censoring 
Censoring occurs when the value of an observation is only partially known which can be 
caused by loss to follow up or administrative censoring (53). Censoring should be 
considered to make sure the individuals still under observation are representative of the 
study population. Otherwise the results may be biased (57).  
Different regression models have been developed for cost modelling to address the 
issues of cost data. In general, in cases of no censoring and no zero-costs, the log-
gamma generalised linear model (GLM) is favoured, which deals with non-normality and 
avoids back-transformation issues (58). Back-transformation issues indicate that if 
geometric means (means on log scale rather than the logged means) were obtained, it 
would be difficult to interpret the coefficient results (59, 60). Regarding the zero-cost 
issues, the two-part mixed model is the most informative by showing the possibility of 
any expenditure first. For the censoring issues, a regression model can be used which 
is weighted by the probability of not being censored. There is no unique model that can 
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deal with all the problems, and the final choice depends on the type and design of the 
study. In the case study of costing analysis, I have checked different regression models 
comparing different distribution assumptions. The model that best fit the data based on 
model selection criteria was selected for further analysis.  
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2.3 Background to breast cancer 
The objective of this section is to provide a background to breast cancer, including 
screening, genetic testing, and treatment. 
Breast cancer is the most common cancer among women worldwide. Globally, 2.1 million 
new cases of breast cancer were diagnosed in 2018, contributing to more than 24% of 
female cancer incident cases (61). The incidence rates of breast cancer vary between 
world regions (62). In more developed regions, the incidence rates are more than twice 
higher compared to less developed regions (93.6 per 100,000 person-years in the UK, 
84.9 per 100,000 person-years in the US, and 36.1 per 100,000 person-years in China 
in 2018) (63). Breast cancer risk is associated with lifestyle and environmental factors 
(64). In HICs, the most important contributor is being overweight and obese, whereas in 
LMICs the lack of physical activity is the most important determinant (65).   
Within China, the breast cancer incidence rate in rural areas is lower than the rate in 
urban areas. However, the mortality from the disease among women residing in rural 
areas is higher due to poorer survival (66). Marked urban-rural differences in breast 
cancer stage at diagnosis (67) and survival have been reported (68), with rural women 
being diagnosed at an advanced stage and thus having poorer five-year survival (51.9%–
60.3%) than their urban counterparts (75.7%–79.9%) (68). 
Breast cancer is potentially a curable disease if diagnosed and treated at an early stage. 
The Surveillance, Epidemiology, and End Results Programme reported that breast 
cancer patients diagnosed at an early stage (Stage I/II) have a better prognosis (5-year 
survival rate of 85%-98%). In contrast, cases diagnosed with advanced breast cancer 
(Stage III/IV) have a poor 5-year survival rate of 30%-70% (69). Early detection in order 
to improve breast cancer outcome and survival remains the cornerstone of breast cancer 
control (70). 
The breast cancer TNM staging system is commonly used to stage breast cancer, while 
the current practice is to use the International Federation of Gynaecology and Obstetrics 
(FIGO) classification system by assigning the number of 0, I, II, III, and IV to group these 
TNM combinations. The relationship between FIGO and TNM classification is detailed in 
Appendix-1. 
2.3.1 Breast cancer screening 
Clinical downstaging and screening are two different but complementary approaches to 
achieving early detection of breast cancer (71). Clinical downstaging is the early 
diagnosis in the symptomatic population, aiming to ensure that symptomatic women are 
diagnosed with early (Stage I/II) and curable breast cancer rather than advanced (Stage 
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III/IV), mainly incurable disease (72). Downstaging could reduce breast cancer mortality, 
primarily through the initiation of effective treatments earlier. The other method is breast 
cancer screening in the asymptomatic population with screening technologies such as 
mammography, ultrasound, and clinical breast examination (CBE, also used in clinical 
downstaging).  
Mammographic screening (using X-rays to examine breasts) has been widely adopted 
in HICs for over 30 years. It is capable of detecting some tumours several years before 
they would be palpable (73). The primary determinant of mammographic screening 
accuracy is breast density. Compared to fatty breasts, mammographic screening is more 
likely to miss breast cancers in radiographically dense breasts (74). Since an inverse 
relationship has been found between patient age and breast density, women at younger 
ages have denser breast and therefore they are more likely to have false-negative results 
(73). Chinese women’s peak age of breast cancer diagnosis is between 45 and 55, which 
is about ten years younger than that of Caucasian women (75, 76). Chinese women tend 
to have dense breasts (77, 78), leading to mammography having lower accuracy and 
being less effective (79-81). Many studies have shown that breast ultrasound has the 
potential of detecting small invasive breast cancers in women with dense breasts not 
detected by mammography, thus improving the effectiveness of screening (82-86).  
In LMICs mammographic breast cancer screening is prohibitively expensive and a 
cheaper alternative option is to use ultrasound as the primary screening test. China 
recommends ultrasound, as opposed to mammography, as the primary screening test. 
In 2009, China launched a breast cancer screening programme for rural women aged 
35-64 years with clinical breast examination coupled with ultrasound as the primary tool. 
Those women found to have a positive result are further tested by biopsy for diagnostic 
confirmation whereas those with a suspicious result, or with insufficient information, 
undergo mammography. If the mammography result is positive a biopsy is performed for 
diagnostic confirmation. If the mammography result is suspicious or provides insufficient 
information, doctors will use their clinical judgment to decide whether a biopsy is required 
to reach a final conclusion (17). The screening flow is presented in Figure 2-2. 
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Figure 2-2 Breast cancer screening flow in rural China 
 
In 2012, China launched a risk-based cancer screening programme for urban women 
aged 40-69 years to screen common cancers including breast cancer. To measure the 
individual risk of breast cancer, health professionals invited women to health facilities 
and used paper-based questionnaires to collect information on individual breast cancer 
exposure (16). The health professionals then used the Harvard Cancer Index online tool, 
now called Your Disease Risk, to process the collected information and identify women 
at high risk of developing breast cancer. High-risk women aged 40-44 years are 
screened by ultrasound and the women with suspected results are further examined by 
mammography. Women with a suspicious mammography result are tested by biopsy for 
diagnostic confirmation. High-risk women aged 45-69 years are screened by both 
mammography and ultrasound, and suspected results from either method are confirmed 
with biopsy (16). The screening flow is presented in Figure 2-3. 
These two pilot programmes of breast cancer screening are still ongoing in China.  
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Figure 2-3 Breast cancer screening flow in urban China 
 
In Chapter 3 (first part 3.1), I reviewed the literature on economics of breast cancer 
screening in LMICs. Since there was no economic evidence of the two pilot breast cancer 
screening programmes in China, I evaluated the cost-effectiveness of the risk-based 
breast cancer screening programme in urban China (Chapter 4) and the population-
based breast cancer screening programme in rural China (Chapter 5).  
2.3.2 Breast cancer genetic testing 
BRCA1, BRCA2, and PALB2 are the three most common genes that can mutate and 
increase the risk of breast cancer. A harmful mutation could be inherited from either 
parent, and each child of a parent who carries a mutation in these genes has a 50% 
chance of inheriting the mutation. BRCA1/BRCA2 carriers have a 17-44% risk of 
developing ovarian cancer and 69-72% risk of developing breast cancer up to age 80 
years (87). PALB2 is a more recently established moderate penetrance breast cancer 
gene, testing for which is now advocated. PALB2 carriers have a 44% risk of breast 
cancer up to age 80 years (88). 
Identifying mutation carriers provides the opportunity for early diagnosis and prevention 
of breast cancer. There are a number of risk management options for unaffected women 
with known mutations. To reduce breast cancer risk, BRCA1/BRCA2/PALB2 mutation 
carriers can be offered enhanced MRI/mammography screening (89), risk-reducing 
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mastectomy (RRM) (90), or chemoprevention with selective estrogen-receptor-
modulators (91). To reduce ovarian cancer risk, BRCA1/BRCA2 mutation carriers can 
opt for risk-reducing salpingo-oophorectomy (RRSO) (92, 93). For patients that have 
already been diagnosed with unilateral breast cancer (cancer in one breast), mutation 
carriers can choose contralateral prophylactic mastectomy (CPM) (preventative 
mastectomy on the other breast) to reduce their risk of developing contralateral breast 
cancer as well as surgical prevention for ovarian cancer. Cancer-affected carriers may 
become eligible for treatment with novel drugs (like poly ADP ribose polymerase (PARP) 
inhibitors, a group of oral pharmacological inhibitors for targeted therapy) and newer 
precision medicine based therapeutics through clinical trials. Therefore, knowing genetic 
mutation status is important for breast cancer clinical management and overall prognosis.  
Current national and international guidelines recommend genetic testing in individuals 
who fulfill recognised/established family-history or clinical-criteria. These criteria are 
surrogates for BRCA probability with testing offered at around a ≥10% probability of 
being a BRCA-carrier (22). However, people with genetic mutations do not always have 
a positive family history and these criteria can miss a large proportion (~50%) of mutation 
carriers (21, 24, 25). Also, family history/criteria-based strategy is dependent on patient 
and their doctor’s awareness of and understanding the importance of their family history, 
the accuracy of family history, communication within/between families and timely 
referrals to clinical genetics. Limited health professional/public awareness and 
complexity of the current structure and testing pathway has fostered restricted access 
and massive under-utilisation of genetic testing services (94-96). Unfortunately, this 
gate-keeper approach has resulted in only 20%-30% of patients eligible for testing being 
referred for this, missing huge opportunities for precision prevention (94). 
An alternative option is to offer panel BRCA1/BRCA2/PALB2 genetic testing for all breast 
cancer cases instead of the current practice of family-history/clinical-criteria based 
genetic (BRCA)-testing. A further advantage is the opportunity to test relatives of breast 
cancer patients. This offers the potential to identify relatives carrying mutations and the 
opportunity for early diagnosis and prevention of cancer as they are at higher risk.  
In Chapter 3 (second part 3.2) I reviewed the literature on economics of genetic testing 
for breast cancer patients in HICs. In Chapter 6, I compared the downstream health 
impacts, costs, and cost-effectiveness of panel BRCA1/BRCA2/PALB2 genetic testing 
for all breast cancer cases with the current practice of BRCA testing based on family 
history/clinical criteria in the US and UK settings. I have obtained data from four large 
breast cancer clinical trials/research cohorts and used a microsimulation model to 
conduct the cost-effectiveness analysis. The microsimulation model permits individual 
heterogeneity in gene types and ages, and can track individual patient history if the 
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memory of events (e.g. risk-reducing options for breast cancer and ovarian cancer) 
impacts future cycles. 
2.3.3 Breast cancer treatment 
Treatment options for breast cancer consist of surgery, radiotherapy, chemotherapy, 
endocrine therapy, and targeted therapy. There are three important receptors for breast 
cancer: estrogen receptor (ER), progesterone receptor (PgR), and human epidermal 
growth factor receptor 2 (HER2).  
Surgery 
Breast resection surgeries include breast-conserving surgery, mastectomy, and 
mastectomy with reconstruction. Breast-conserving surgery is the removal of the 
cancerous lump. Studies have shown that breast-conserving surgery followed by 
radiotherapy is as successful as mastectomy at treating early-stage breast cancer (97). 
Mastectomy is the removal of all the breast tissue. Reconstruction can be carried out at 
the same time as a mastectomy (immediate reconstruction) or later (delayed 
reconstruction) (97). 
The types of lymph node involvement procedures are directed by axillary ultrasound (+/- 
axillary biopsy) findings. If the ultrasound assessment and histological assessment of the 
axilla show that cancer has spread to the axillary lymph node, a patient will typically have 
axillary lymph node dissection (ALND) which removes all the axillary lymph nodes. If the 
ultrasound shows no evidence of cancer spread, patients undergo sentinel node biopsy 
(SNB) which involves the removal and examination of the first few lymph node/s (sentinel 
node/s) to which a tumour is likely to spread. If the sentinel node contains 
macrometastatic (a tumour deposit in a lymph node with a diameter>2mm) involvement 
with cancer, a patient may go on to have an ALND (98) or in some circumstances may 
have axillary radiotherapy as an alternative axillary treatment.  
Radiotherapy and chemotherapy 
Radiotherapy uses controlled doses of radiation to kill remaining cancer cells usually 
after surgery or chemotherapy. Chemotherapy involves using cytotoxic medication to kill 
cancer cells, including both neoadjuvant chemotherapy before surgery to shrink a large 
tumour and adjuvant chemotherapy after surgery to destroy remaining cancer cells. For 
patients with early breast cancer, preoperative chemotherapy is proved to be equally 
effective as postoperative chemotherapy regarding survival (99).  
Endocrine therapy 
Endocrine therapy is given to hormone receptor-positive breast cancer. ER+ cancer cells 
depend on estrogen for growth, so drugs blocking the estrogen effects can be used for 
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treatment (e.g. tamoxifen) (100). In most cases, endocrine therapy lasts a total of five 
years (97).  
Targeted therapy 
Targeted therapy is given to patients with HER2+ breast cancer. HER2+ breast cancers 
are generally more aggressive than HER2- breast cancers (101), but HER2+ cancer cells 
respond to drugs such as the monoclonal antibody trastuzumab (102).  
The general therapy strategies are summarised for patients with early breast cancer 
(Figure 2-4) (100) and metastatic breast cancer (Figure 2-5) (103), which can be 
individualised based on disease characteristics and patient characteristics (104).  
 
Figure 2-4 Systematic therapy strategies in early breast cancer 
 
 
Figure 2-5 Systematic therapy strategies in metastatic breast cancer 
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Although the case for earlier diagnosis with respect to survival has been well made, the 
financial implications are not well understood (105, 106). Stage of disease at diagnosis 
is an important predictor of treatment costs. Treatment for more advanced disease is 
often more intensive or invasive than treatment for the earlier stages (105). As a result, 
a more advanced stage tends to be associated with more resource utilisation in addition 
to poorer health outcomes (107).  
Treatment costs by stage at diagnosis are important in quantifying the gains from early 
detection. If early treatment lowers costs, this will help offset some cost of interventions 
for earlier diagnosis and treatment. In addition, treatment costs by stage would be 
valuable to inform the cost-effectiveness studies for treatment or preventative 
interventions of breast cancer. However, the mean costs by stage do not reveal the 
heterogeneity across patients. Patient-level data can contain information such as 
socioeconomic group, medical history, and treatment options, thus allowing the 
comparison of costs across patient subgroups and identification of cost predictors. 
Therefore, it is important to analyse the costs of breast cancer treatment by stage at 
diagnosis using patient-level data.  
In Chapter 7, I conducted a systematic review to compare treatment costs of breast 
cancer by stage at diagnosis across countries. UK data on the costs of breast cancer 
treatment by stage at diagnosis are out-of-date and were published over 20 years ago 
(26). Recent NICE appraisals on the cost-effectiveness of breast cancer treatments have 
instead relied on modelled assumptions (27). Up-to-date estimates of the costs of breast 
cancer treatments by stage are thus required. In Chapter 8, I used patient-level data from 
women aged 50 years and over diagnosed with early invasive breast cancer in England 
to estimate the costs of breast cancer care by stage at diagnosis, and explore to what 
extent the breast cancer costs vary across different patient groups and regions. 
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Chapter 3 Literature review on modelling 
The aims of this Chapter are: (i) to review the literature on economic evaluation of breast 
cancer screening in low- and middle-income countries (LIMCs); and (ii) to review the 
literature on economic evaluation of breast cancer genetic testing in high-income 
countries (HICs). 
3.1 Economic evaluation of breast cancer screening in LMICs 
3.1.1 Introduction 
Breast cancer incidence rates in LMICs are lower but survival rates are poorer than the 
rates in HICs (62). The poor prognosis of breast cancer in LMICs is mainly related to the 
disadvantage in access to breast cancer screening and treatment (108, 109). Breast 
cancer screening programs in LMICs are often hampered by limited health resources 
(110). Also, LMICs often lack evidence-based information on breast cancer screening 
strategies in contrast to the established strategies in HICs (111-115). Due to the 
differences in population characteristics and the functioning of health systems, LMICs 
cannot adopt the results in HICs and need to develop their own breast cancer screening 
strategies. 
An earlier study reviewed economic studies about breast cancer control (screening, 
diagnostic, and therapeutic interventions) in LMICs published until January 2013 (111). 
Studies in Mexico, Poland, Turkey identified mammography screening as a cost-effective 
intervention (1-4), whereas studies in India, Ghana, and Egypt found other strategies 
(such as clinical breast examination screening or mass-media awareness raising) to be 
more economically attractive (5-7). The systematic review argued that more economic 
analyses of better quality should be conducted to give more clear recommendations 
(111). Updated evidence is required on economic analyses of breast cancer screening 
in LMICs after 2013. In this section, I undertook a systematic review to update the 
economic evidence on breast cancer screening in LMICs. 
3.1.2 Method 
Eligibility criteria 
The inclusion criteria were based on the PICOS framework: (i) population: asymptomatic 
women in LMICs; (ii) intervention: any form of breast cancer screening; (iii) comparator: 
not restricted; (iv) outcome: incremental cost-effectiveness ratio; and (v) study design: 
modelling studies or trial-based economic evaluations.  
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I excluded studies with the following characteristics: (i) only costs or clinical efficacy 
reported; (ii) cost minimisation analysis; (ii) budget impact analysis alone but without 
cost-effectiveness or cost-utility analysis; (iv) review articles.  
Eligibility criteria 
I searched MEDLINE(R) (2013 to Week 2 March 2019) and EMBASE Classic + EMBASE 
(2013 to 15 March 2019) with search terms presented in Appendix-2. I employed 
Cochrane LMIC Filters to limit the studies to low- and middle-income countries (116). 
Also, reference lists from relevant primary studies and review articles were used to 
identify other relevant publications. My search was limited to publications in English. 
Titles and abstracts were first reviewed, and full-texts of the studies that potentially met 
the eligibility criteria were retrieved and full-text reviewed. 
Data extraction  
I extracted the study characteristics including settings, population, interventions, 
comparators, and conclusions. Also, I documented the following methodological 
characteristics: economic evaluation types, perspectives of analysis, study designs, time 
horizons, sources for costs, sources for clinical effectiveness, outcome measures, 
discount rates, incremental analyses, and sensitivity analyses. 
Economic evaluation types are categorised as cost-effectiveness, cost-utility analysis 
cost-benefit analysis, and cost-minimisation analysis. Study designs include 
experimental, observational (cohort, case-control, or cross-sectional), Markov model-
based, and decision tree model-based. I classified the sources for estimation of 
effectiveness and resource utilization by primary data collection (e.g. questionnaires, 
patients), secondary data collection (e.g. unit cost lists), literature, and expert opinion. 
Also I documented whether future costs and health effects were discounted to reflect the 
positive time preference. I also summarised whether incremental analyses and 
sensitivity analyses were conducted.  
Critical appraisal 
The established Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist (117) was employed to assess the reporting quality of the reviewed 
studies. A three-point response scale was used to grade the quality of each item on the 
checklist, ranging from 0 (not considered), through 1 (partially considered), to 2 (fully 
considered) (118). I summed up all scores and compared this with the maximum 
attainable score to calculate the percentage of the maximum attainable score.  
3.1.3 Results 
Search results 
 37 
The search took place in March 2019 and the stepwise selection flow of articles is 
presented in Figure 3-1. The MEDLINE and the EMBASE search yielded 52 and 176 
possible studies respectively. The collective searches yielded 193 unique studies after 
removing duplicates. Based on the eligibility criteria, I excluded 185 studies and included 
eight studies in this review. 
 
Figure 3-1 Breast cancer screening – study flow diagram 
 
Study characteristics  
Table 3-1 describes the baseline characteristics of the eight included studies. I found five 
studies from Asia including Iran (n=2), Vietnam (n=2), China (n=1), two from Latin 
America including Peru (n=1), Costa Rica and Mexico (n=1), and one on a sub-regional 
level from Southeast Asia and eastern sub-Saharan Africa (n=1).  
Five studies evaluated breast cancer screening interventions alone (8-12). The other 
three studies compared a variety of breast cancer-related intervention scenarios, 
including screening, early detection, palliative, or treatment interventions (13-15). These 
three studies allowed a situation that no interventions were implemented, where the 
counterfactual acted as a reference to compare all possible interventions (119).  
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The studies in Vietnam and Peru identified mammography screening as cost-effective 
(11, 13), whereas studies in Iran provided evidence that mammography screening was 
not cost-effective mainly due to screening harms (9, 10). Some other screening 
strategies have been shown to be economically attractive, such as clinical breast 
examination (CBE) in Vietnam and Costa Rica (8, 14), mass-media awareness in Mexico 
(14), and CBE followed by mammography and ultrasound in China (12).  
The study for Southeast Asia and eastern sub-Saharan Africa compared three breast 
cancer interventions, including: (1) screening with mammography every two years for 
50-59 years linked with timely diagnosis and treatment; (2) treatment of breast cancer 
stages I and II with surgery and/or systematic therapy; (3) basic palliative care for breast 
cancer. The study showed that the treatment of breast cancer (Stage I and II) with 
surgery and/or systematic therapy at 95% coverage was the most cost-effective 
intervention in both regions (15).  
Methodological characteristics  
Table 3-2 presents the methodological characteristics of the reviewed articles. The 
majority of studies combined both costs and effects in a single cost-effectiveness 
estimate (n=7). One experimental study reported costs and effects separately (9). The 
majority of these conducted cost-utility analysis based on Markov models, measuring 
health outcomes in QALYs (10, 12, 15) or DALYs (13, 14). Other outcome measures 
were also used such as life years gained (8, 11) and the number of cases detected (9). 
Most studies used the payer perspective (n=6), one used the social perspective (12), 
and one did not present the perspective (15). The time horizons among the reviewed 
studies varied between one year and a lifetime horizon. One-way sensitivity analyses (8, 
10-12, 14), probabilistic sensitivity analyses (8, 10, 12, 15) and scenario analyse (9, 13) 
were conducted to explore the uncertainty. 
Study quality 
The quality of the reviewed studies is presented in Table 3-3, as indicated by the 
percentage score ranging from 72.7% to 97.7%. Studies by Nguyen et al. (8) had the 
highest total scores among the reviewed papers. The average score for titles and 
abstracts was 84.4%, measuring whether the studies reported all the elements in titles 
and abstracts so they could be identified as economic evaluation studies. On the 
methodological domain, studies scored 89.7% of the maximum obtainable score across 
all studies. The average scores for results and discussion were 62.5% and 87.5% 
respectively.  
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3.1.4 Discussion 
This study supplemented the economic evidence from eight studies after 2013 to the 
existing studies about breast cancer screening in LMICs identified in the earlier 
systematic review (111).  
Although mammography-based screening strategies have been widely adopted in 
developed countries for over 30 years, this study suggests that there is mixed evidence 
on the cost-effectiveness of mammography screening in LMICs. Mammography was 
shown to be not economically attractive in Iran (9, 10), but it was good value for money 
in Vietnam and Peru (11, 13). My results are consistent with the inconclusive economic 
evidence on mammography screening from the previous literature review in 2013 (111).  
The inconsistent results of the reviewed cost-effectiveness studies on mammography 
screening for breast cancer are partly due to the debatable effectiveness of 
mammography. Although mammographic screening has been shown to reduce breast 
cancer mortality by 20%, it is associated with considerable harm in terms of 
overdiagnosis (120). Carcinoma in situ is much more likely to be detected by 
mammography screening, but more than half of the cases will not progress to be invasive 
cancer (121). Also, some identified tumours may be slow-growing that would never have 
been clinically apparent before a woman dies from another cause (73). Overdiagnosis 
could undermine the quality of life because women would experience important 
psychological distress (122). In addition, mammography for breast cancer screening is 
prohibitively expensive in LMICs. This also makes mammography as the primary 
screening tool less cost-effective in LMICs. More economic evidence on mammography 
screening is required to determine its economic attractiveness in LMICs.  
It was emphasised in 2013 that there was very little economic evidence on the less 
established interventions such as tactile imaging, awareness raising, clinical breast 
examination screening, or palliative interventions in LMICs (111). Over the past years, 
some screening methods have been shown to be cost-effective such as CBE in Vietnam 
and Costa Rica (8, 14), CBE followed by mammography and ultrasound in China (12), 
and mass-media awareness raising in Mexico (14). However, the evidence is still 
insufficient and economic studies should aim to evaluate these interventions more often. 
The quality of the reviewed articles over the past five years has improved compared to 
those published before 2013, of which the majority failed to score at least 50% on every 
domain (111). Among the five reviewed studies in our analysis, the studies on average 
scored 84.7% of the maximum obtainable score. However, we used the latest version of 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist 
(2013) (117) in our review,  rather than the Guidelines for Authors and Peer Reviewers 
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of Economic Submissions to the British Medical Journals in 1996 (123). Therefore, the 
different assessment domains deserve careful consideration. 
The most adopted study design was modelling-based study. Compared to trial-based 
studies, decision models could include multiple relevant comparators and allow sufficient 
time horizon to reflect the changes in costs and health outcomes. Also, modelling-based 
studies could incorporate data from different sources and play an important role in 
extrapolating results to a wider population or a broader setting (37). Markov model is an 
analytical structure with explicit consideration of time and individuals transition between 
health states according to the transition probabilities over stated time cycles. Markov 
model is a good choice for repeat events such as breast cancer screening (124). 
Therefore, we advocate the use of Markov modelling in the economic studies of breast 
cancer control in LMICs.  
This study may be limited by the publication bias, indicating that studies with negative 
outcomes are less likely to be published. Also, as with the previous systematic review of 
economic analyses on breast cancer control, I only searched for articles published in 
English. Ideally, two investigators should independently extract the data and assess the 
study quality. As this systematic review was undertaken by only one investigator, 
potential bias deserves careful considerations. 
In conclusion, our findings indicate that although some more studies have been 
performed, the economic evidence on breast cancer screening interventions in LMICs is 
still insufficient. There is one study providing economic evidence of breast cancer 
screening in China. However, it was a community-level screening programme in one city, 
in which the age group of the target population and screening method were different from 
those in China’s rural or urban breast cancer screening pilot programmes. In Chapter 4, 
I evaluated the cost-effectiveness of risk-based breast cancer screening programmes in 
urban China. In Chapter 5, I analysed the cost-effectiveness of population-based breast 
cancer screening programmes in rural China. 
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3.1.5 Tables  
Table 3-1 Study characteristics of reviewed papers 
Study Setting Population Intervention Comparator Conclusion 
Screening interventions     
Nguyen et al., 2013 (8) Vietnam Asymptomatic 
women aged 40 
years 
An annual CBE 
screening program for 
15 years 
No Screening Annual CBE screening is cost-
effective at 3*GDP per capita. 
Barfar et al., 2014 (9) Iran Asymptomatic 
women aged 35 
years and over 
Mammography 
screening 
No Screening Mammography screening is not 
cost-effective. 
Haghighat et al., 2016 
(10) 
Iran Asymptomatic 
women aged 40-
70 years 
Three rounds of 
organised triennial 
mammography 
screening 
No Screening The first round of screening is 
cost-effective but the second and 
third rounds are not cost-effective 
at 3*GDP per capita. 
Nguyen et al., 2018 (11) Vietnam Asymptomatic 
women aged 45-
64 years 
One round of 
mammography 
screening 
No screening One round of mammography 
screening to women aged 50–59 
years is cost-effective at 3*GDP 
per capita. 
Yang et al., 2018 (12) China Asymptomatic 
women aged 35-
69 years 
BCE and 
mammography followed 
by ultrasound 
No screening Annual community-based 
screening is cost-effective at 
3*GDP per capita. 
Multiple interventions      
Zelle et al., 2013 (13) Peru Depends on the 
interventions 
94 breast cancer-
related interventions 
No intervention 
(WHO-CHOICE) 
A combined mobile and fixed 
mammography screening 
triennially is the most cost-
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effective. Triennial CBE, and CBE 
combined with fixed 
mammography screening, are 
more feasible and also cost-
effective.  
Niens et al., 2014 (14) Costa Rica, 
Mexico 
Depends on the 
interventions 
19 breast cancer-
related interventions 
No intervention 
(WHO-CHOICE) 
In Costa Rica, the current 
strategy of treating breast cancer 
in stages I to IV at an 80% 
coverage level is the most cost-
effective. At a coverage level of 
95%, biennial CBE screening 
could be very cost-effective. In 
Mexico, a mass-media awareness 
raising program at 95% coverage 
could be the most cost-effective 
with the threshold of GDP and 
3*GDP per capita. 
Ralaidovy et al., 2018 
(15) 
Southeast 
Asia,  Eastern 
Sub-Saharan 
African 
Depends on the 
interventions 
Three breast cancer-
related interventions 
No intervention 
(WHO-CHOICE) 
The treatment of breast cancer 
(Stage I and II) with surgery 
and/or systematic therapy at 95% 
coverage is the most cost-
effective intervention in both 
regions. 
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Table 3-2 Methodological characteristics of reviewed papers 
Study Type Perspective Study design Time 
horizon 
Sources for 
costs 
Sources for 
effectiveness 
Outcome 
measure 
Discount  Incremental 
analysis 
Sensitivity 
analysis 
Nguyen et al., 
2013 (8) 
CEA Payer Markov Lifetime Secondary/ 
Literature 
Literature LYG Yes Yes One-way 
and PSA 
Barfar et al., 
2014 (9) 
Costs and 
effects 
separately 
Payer Experimental  1 year Primary Primary data Cases 
detected 
No No Scenario 
analysis 
Haghighat et 
al., 2016 (10) 
CUA Payer Decision tree 
and Markov  
50 
years 
Literature Literature QALY Yes Yes One-way 
and PSA 
Nguyen et al., 
2018 (11) 
CEA Payer Markov Lifetime Secondary/ 
Literature 
Literature LYG Yes Yes One-way 
and PSA 
Yang et al., 
2018 (12) 
CUA Societal Markov Lifetime Literature Literature QALY Yes Yes One-way 
and PSA 
           
Zelle et al., 
2013 (13) 
CUA Payer Markov Lifetime Secondary/ 
Literature 
Literature DALY Yes No Scenario 
analysis 
Niens et al., 
2014 (14) 
CUA Payer Markov  100 
years 
Secondary/
Expert 
opinion 
Literature DALY Yes No One way  
Ralaidovy et 
al., 2018  (15) 
CUA NA Markov NA Secondary Literature QALY Yes Yes NA 
*LYG: life year gained; QALY: quality-adjusted life year; DALY: disability-adjusted life year; PSA: probabilistic sensitivity analysis; CEA: cost-effectiveness analysis; CUA: cost-utility 
analysis  
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Table 3-3 Quality assessment of reviewed studies using CHEERS checklist 
Study Title and abstract Introduction Methods Results Discussion Sum of scores 
Nguyen et al., 2013 (8) 4 (100%) 2 (100%) 27 (96.4%) 8 (100%) 2 (100%) 43 (97.7%) 
Barfar et al., 2014 (9) 4 (100%) 2 (100%) 27 (96.4%) 4 (50%) 0 (0%) 37 (84.1%) 
Haghighat et al., 2016 (10) 3 (75%) 2 (100%) 23 (82.1%) 5 (62.5%) 2 (100%) 35 (79.5%) 
Nguyen et al., 2018 (11) 4 (100%) 2 (100%) 26 (92.9%) 8 (100%) 2 (100%) 42 (95.5%) 
Yang et al., 2018 (12) 2 (50%) 2 (100%) 25 (89.3%) 6 (75%) 2 (100%) 37 (84.1%) 
Zelle et al., 2013 (13) 3 (75%) 2 (100%) 26 (92.9%) 3 (37.5%) 2 (100%) 36 (81.8%) 
Niens et al., 2014 (14) 3 (75%) 2 (100%) 26 (92.9%) 3 (37.5%) 2 (100%) 36 (81.8%) 
Ralaidovy et al., 2018 (15) 4 (100%) 2 (100%) 21 (75%) 3 (37.5%) 2 (100%) 32 (72.7%) 
Average 3.4 (84.4%) 2 (100%) 25.1 (89.7%) 5 (62.5%) 1.8 (87.5%) 37.3 (84.7%) 
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3.2 Economic evaluation of genetic testing in HICs 
3.2.1 Introduction 
A systematic review has been performed on economic evaluations of healthcare 
programmes involving BRCA testing, searching studies until December 2014 (125). Nine 
economic evaluations were included and four categories of BRCA testing programmes 
were identified, including (i) testing population-based individuals without cancer (126-
129), (ii) testing individuals without cancer but with family history-suggestive of BRCA 
mutation (129, 130), (iii) testing patients with BRCA-related cancers (131), and (iv) 
testing patients with BRCA-related cancers and their cancer-free relatives sequentially if 
a mutation was identified (18-20).  
Specifically for economic evaluations on testing women with BRCA-related cancers and 
cascade testing of relatives of the index cases, all the three studies showed some 
evidence for cost-effectiveness (18-20). In the two studies in Spain and the US (19, 20), 
genetic tests were offered to affected women at risk for inherited breast/ovarian cancer 
according to personal and familial criteria. Another Norwegian study compared genetic 
testing of all incident breast and ovarian cancers with family history-based testing (18). 
However, this study is outdated, published 20 years ago, and only took BRCA1 mutation 
into consideration.  
In this section, I reviewed relevant papers published after December 2014 to find out 
whether there is any updated economic evidence on unselected testing of breast cancer 
patients and cascade testing of relatives of index cases.  
3.2.2 Method 
The inclusion criteria were based on the PICOS framework: (i) population: breast cancer 
patients; (ii) intervention: genetic testing to breast cancer patients and cascade testing 
of relatives; (iii) comparator: not restricted; (iv) outcome: incremental cost-effectiveness 
ratio; and (v) study design: modelling studies or trial-based economic evaluations. The 
exclusion criteria were: (i) only costs or clinical efficacy reported; (ii) cost minimisation 
analysis; (ii) budget impact analysis alone but without cost-effectiveness or cost-utility 
analysis; (iv) review articles.  
I searched MEDLINE(R) (2015 to Week 2 March 2019) and EMBASE Classic + EMBASE 
(2015 to 15 March 2019) to search papers published after 2015 (search terms in 
Appendix-3). Titles and abstracts were first reviewed, and full-texts of the studies that 
potentially met the eligibility criteria were retrieved and full-text reviewed. 
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3.2.3 Results 
The study flow diagram is presented in Figure 3-2. The MEDLINE, the EMBASE, and 
other sources yielded 27 possible studies. Based on the eligibility criteria, only one study 
about cost-effectiveness of unselected genetic testing in breast cancer patients was 
identified in Norway.  
 
Figure 3-2 Breast cancer genetic testing – study flow diagram 
 
The Norwegian study used a decision tree-based model to evaluate the lifetime cost-
effectiveness of genetic testing all patients with breast cancer and their unaffected 
relatives compared to testing based on family history. Breast cancer patients with 
BRCA1/BRCA2 mutations can choose risk-reducing salpingo-oophorectomy (RRSO) to 
reduce ovarian cancer. Unaffected BRCA1/BRCA2 mutation carriers can choose risk-
reducing mastectomy (RRM) to reduce breast cancer risk and RRSO to reduce ovarian 
cancer risk. The analysis was conducted from the payer and the societal perspectives, 
with data employed from 535 breast cancer patients (21). Life years gained were used 
to measure health outcomes. It was reported that the ICER was lower than the frequently 
used WTP thresholds, and thus BRCA testing of all breast patients was economically 
superior to family-history approach. The sensitivity analysis documented that the cost of 
genetic test was the prominent parameter affecting the results.   
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3.2.4 Discussion 
In conclusion, there is only a recent small Norwegian study (535 patients) showing the 
cost-effectiveness of BRCA-testing all breast cancer patients. In Chapter 6, I obtained 
data from 11,836 population-based breast cancer patients regardless of family history 
from four large research studies to estimate the lifetime cost-effectiveness of multigene-
testing (BRCA1/BRCA2/PALB2) all breast patients in the UK and US, which is both 
broader in scope and draws on a much larger sample-size of population-based breast 
cancer patients.  
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Chapter 4 
Cost-effectiveness of risk-based breast cancer screening programme in urban 
China 
Chapter 4 evaluates the cost-effectiveness of breast cancer screening programmes in 
urban China. I conceived the research question, developed the Markov model, collected 
the data, discussed the results and wrote the manuscript. Professor Isabel dos Santos 
Silva helped revise the Markov model to simulate the disease progression better. Dr 
Rosa Legood, Dr Zia Sadique, and Dr Li Yang gave comments and suggestions on 
findings and interpretations. All authors approved the final draft prior to journal 
submission and inclusion in the thesis. This paper has been published by Bulletin of the 
World Health Organisation.  
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Commentary 
The treatment costs of breast cancer by stage obtained from the literature were lifetime 
costs. In the model, the costs were one-off costs and the utilities were on an annual basis 
according to the health states. 
Based on a systematic review supplemented by relevant randomised trials and values in 
previous models (132-136), the loss of quality of life from false positive results is 5% and 
the duration of loss is 0.2 years, which corresponds to 0.01 QALYs decrement in the 
year of screening. With the 0.01 QALYs loss from false positives in the screening year 
incorporated in the model, the baseline model of annual risk-based screening would yield 
an ICER of US$ 6,645/QALY, suggesting the urban breast cancer screening programme 
to be cost-effective. In the one-way sensitivity analysis, the loss of quality of life from 
false positive results over the 0.2 years was varied from 5% to 34% (137), leading to the 
QALYs decrement from 0.01 to 0.068 in the screening year. This results in the ICERs of 
US $6,645/QALY – US$ 6,960/QALY, which does not change the conclusion that the 
risk-based screening for the asymptomatic disease was economically attractive in urban 
China in the one-way sensitivity analysis.  
This study is subject to some limitations. Firstly, a systematic literature review of the 
evidence for the parameter inputs was not conducted to inform the model. This might 
potentially lead to biased inputs based on single study estimates. Secondly, the 
uncertainty ranges of some parameters such as progression rates were not available. 
The uncertainty of the resulting incremental cost-effectiveness ratios could therefore be 
underestimated. Thirdly, another limitation of the model is the annual cycle length, 
assuming the transitions between health states are unable to occur within one year. 
Fourthly, the analysis is limited by parameter correlations not accounted for in the 
probabilistic sensitivity analysis. In future research, input correlations could be included 
to reduce decision uncertainty. 
In Table-1, the minimum and maximum values of effectiveness of screening and utility 
scores should have been labelled as lower and upper limits of 95% confidence intervals. 
The confidence intervals of costs were not available from the literature and therefore 
costs were varied by ±30% as the minimum and maximum values in the one-way 
sensitivity analysis. In Table-2, the baseline analysis corresponds to a screened woman 
(annual screening arm) and a non-screened woman (no screening arm) respectively. 
The scenario analyses correspond to a screened woman. In Figure-2, patients at 
different stages can die from breast cancer with different fatality rates. This diagram 
should be updated as below. 
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Updated Fig 2. Natural history model for breast cancer progression, China 
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Chapter 5 
Cost-effectiveness of population-based breast cancer screening programme in 
rural China 
Chapter 5 evaluates the cost-effectiveness of breast cancer screening programmes in 
rural China. I conceived the research question, developed the Markov model, collected 
the data, discussed the results and wrote the manuscript. Professor Isabel dos Santos 
Silva helped revise the Markov model. Dr Rosa Legood, Dr Zia Sadique, and Dr Li Yang 
gave comments and suggestions on findings and interpretations. All authors approved 
the final draft prior to journal submission and inclusion in the thesis. This paper has been 
published by the International Journal of Cancer.  
 
 66 
 
  
 67 
 
  
 68 
 
  
 69 
 
  
 70 
 
  
 71 
 
  
 72 
 
  
 73 
 
  
 74 
 
 
 
 75 
Appendix-S1 
Cost-effectiveness acceptability curve 
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Commentary 
Based on a systematic review supplemented by relevant randomised trials and values in 
previous models (132-136), the loss of quality of life from false positive results is 5% and 
the duration of loss is 0.2 years, which corresponds to 0.01 QALYs decrement in the 
year of screening. With the 0.01 QALYs loss from false positives in the screening year 
incorporated in the model, the baseline model of annual population-based screening 
would yield an ICER of US$ 6,879/QALY, suggesting the rural breast cancer screening 
programme to be cost-effective. In the one-way sensitivity analysis, the loss of quality of 
life from false positive results over the 0.2 years was varied from 5% to 34% (137), 
resulting in the ICERs of US $6,879/QALY – US$ -6,511/QALY. With the maximum 34% 
quality of life decrement of full health over 0.2 years (0.068 QALYs decrement), breast 
cancer screening cost $186.7 more and led to a loss of 0.03 QALYs. Compared to no 
screening, annual screening would lead to an extra cost of $6,511 per QALY lost in rural 
China. Therefore, the cost-effectiveness of the rural breast cancer screening programme 
is very uncertain in the one-way sensitivity analysis and breast screening among the 
general population in rural China could potentially harm women’s health due to false 
positives with the current screening tool. A threshold analysis was conducted to explore 
the minimum disutility from false positives at which the ICER reached the willingness-to-
pay threshold of US$ 23,050/QALY to maintain the cost-effectiveness of breast cancer 
screening in the rural programme. The lower limit of disutility from false positives at which 
rural breast cancer screening programme would remain cost-effective at the threshold 
was 0.029 QALYs in the screening year, corresponding to 14.5% quality of life decrement 
of full health over 0.2 years.  
The effectiveness of screening is obtained from a study of 26,224 Chinese women 
participating in the rural breast cancer screening programme (Chu 2014). The screening 
modality for these participants was the same as the measure required for the input to our 
model. The biopsy test was performed for diagnostic confirmation of breast cancer. Due 
to limited evidence on the performance of the screening programme in rural China, I 
explored a 30% reduction in the screening sensitivity and specificity as the lower values 
in the one-way sensitivity analysis. Unfortunately, the length of follow-up was not 
reported in this study. 
One potential limitation is that I assumed the same transition probabilities, treatment 
costs of breast cancer, and utility scores in the rural screening model as those used in 
the urban model due to lack of data, which deserves careful considerations. However, 
some inputs in the rural model were different from those used in the urban model, 
including age-specific invasive breast cancer incidence, effectiveness of screening, and 
screening costs. The urban programme screens high-risk women aged 40–69 years by 
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ultrasound and/or followed by mammography, while the rural programme screens 
women aged 35-64 years with clinical breast examination coupled with ultrasound as the 
primary tool. Therefore, the effectiveness of screening (sensitivity and specificity) and 
the screening costs were different in urban and rural China. In addition, the incidence 
rate of breast cancer in China’s rural areas is significantly lower than that in urban areas 
(17.0 vs. 34.3 per 100,000 person-years in 2009) (138). 
In Table-1, the transition probabilities correspond to one year. The treatment costs of 
breast cancer by stage were lifetime costs. In the model, the costs were one-off costs 
and the utilities were on an annual basis according to the health states. The row titles for 
effectiveness of screening and utility scores should have been labelled as lower and 
upper limits of 95% confidence intervals. The confidence intervals of costs were not 
available from the literature and therefore costs were varied by ±30% as the minimum 
and maximum values in the one-way sensitivity analysis.  
In Figure-2, patients at different stages can die from breast cancer with different fatality 
rates. This diagram should be updated as below. 
 
Updated Figure 2. The Markov model for breast cancer progression 
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Chapter 6 
Cost-effectiveness of multi-gene testing to all patients with breast cancer 
This chapter presents analyses estimating the incremental lifetime effects, costs, and 
cost-effectiveness of offering panel genetic testing to all breast cancer (BC) patients 
compared to current practice of genetic (BRCA) testing for BC patients based on family 
history/clinical-criteria.  
Data were collected from 11,836 population-based BC patients with family history 
information from four large research studies based in the UK, US and Australia. Our 
collaborators are from Wolfson Institute of Preventive Medicine, Manchester University, 
Southampton University, Melbourne University, and Kaiser Permanente Washington 
Health Research Institute. I developed the micro-simulation model from scratch with 
support from Dr Ranjit Manchanda, Dr Rosa Legood, Dr Zia Sadique and Shreeya Patel. 
All authors approved the final draft prior to journal submission and inclusion in the thesis. 
This paper has been published by JAMA Oncology.  
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Commentary 
The willingness-to-pay (WTP) thresholds of £20,000/QALY-£30,000/QALY should have 
been adopted in the UK analysis and $50,000/QALY-$100,000/QALY adopted in the US 
analysis. Compared with the current BRCA testing based on clinical criteria/family history, 
unselected multigene testing for all breast cancer patients would cost £10,464/QALY 
(payer perspective) or £7,216/QALY (societal perspective) in the UK or $65,661/QALY 
(payer perspective) or $61,618/QALY (societal perspective) in the US. The incremental 
cost-effectiveness ratios (ICERs) in the UK are well below the WTP thresholds, while the 
ICERs in the US lie between the lower and upper limits of the thresholds. In the 
probabilistic sensitivity analysis, the cost-effectiveness acceptability curves were plotted 
to show the probability of unselected multigene testing for all breast cancer patients 
being cost-effective at different WTP thresholds in the UK and the US. From the payer 
perspective, unselected multigene testing remained cost-effective for 88% to 98% of UK 
and 5% to 64% of US health system simulations. From the societal perspective, 
unselected multigene testing remained cost-effective for 95% to 99% of UK and 8% to 
68% of US health system simulations.  
The utility score of incident breast cancer is weighted by the proportion of early (95%) 
and advanced (5%) breast cancer, and the utility score of prevalent breast cancer is 
weighted by the proportion of recurrent (8%) and remittent (92%) breast cancer. Similarly, 
the utility score of incident ovarian cancer is weighted by the proportion of early (30%) 
and advanced (70%) ovarian cancer, and the utility score of prevalent breast cancer is 
weighted by the proportion of recurrent (17.6%) and remittent (82.4%) ovarian cancer. 
In the model, the utilities were on an annual basis according to the health states. In the 
first year after diagnosis, patients were assigned the utility score of incident cancer and 
from the second year onwards, patients were assigned the utility score of prevalent 
cancer. In the last year before death, patients were assigned the utility score of end-
stage cancer. 
Potentially there are broader health and non-health benefits related to genetic testing for 
all breast cancer patients. A cost-benefit analysis could be conducted to capture all the 
benefits. However, it is difficult to measure all health and non-health benefits in monetary 
terms. Another limitation is that the disutility related to genetic testing is not considered 
in this study, which may lead to the overestimation of health outcomes in terms of QALYs. 
This deserves careful considerations. Also genetic testing could have important 
consequences beyond health with long-term implications. In this study, it was assumed 
that breast cancer patients and relatives of mutated patients at all ages in the unselected 
testing arm were offered genetic testing. Offering genetic testing to children may raise 
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ethical issues though they would not choose risk-reducing mastectomy until age 37 or 
risk-reducing salpingo-oophorectomy until age 40. 
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Chapter 7  
Global treatment costs of breast cancer by stage: a systematic review 
In this chapter, I report on a review of the literature to compare treatment costs of breast 
cancer across countries at different levels of socio-economic development, and to 
identify methodological differences in costing approaches. I conducted the literature 
review design, methods, and analysis independently with supervision from Dr Rosa 
Legood and Dr Zia Sadique. Shivani Mathur Gaiha and I independently extracted the 
data and assessed the study quality. I have prepared the findings and results as a first 
draft of the manuscript, with comments on drafts from Dr Rosa Legood, Dr Zia Sadique, 
and Professor Isabel dos Santos Silva. All authors approved the final draft prior to journal 
submission and inclusion in the thesis. This paper has been published by PLOS One.  
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S1 Table 
 Searches MEDLINE EMBASE NHS EED 
1 Breast cancer or breast tumor or breast 
tumour or breast neoplasm or mammon 
cancer or mammo tumor or mammo 
tumour or mammo neoplasm 
208573 485451 2043 
2 exp Breast Neoplasms/ 262672 482860 1798 
3 1 or 2 298094 529150 2339 
4 Cost or treatment cost or health service 
cost or drug cost or surgery cost or 
mastectomy cost or breast-conserving 
cost or chemotherapy cost or 
radiotherapy cost or endocrine cost or 
targeted therapy cost 
378394 762229 22534 
5 exp Health Care Costs/ 57935 263288 4990 
6 exp Health Expenditures/ 19239 263288 213 
7 4 or 5 or 6 409040 776053 23053 
8 3 and 7 6009 15490 793 
9 Disease stage or cancer stage or by 
stage or stage-specific 
23486 39578 318 
10 Local and regional and remote 3781 6807 4 
11 I and II and III and IV 63321 104261 255 
12 9 or 10 or 11 89546 148561 549 
13 8 and 12 99 268 36 
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S2 Table 
Study Type Collection Match Description Regression  Censoring Missing data Timing 
Allaire et al, 2017 [15] Claim Micro Yes Mean, UNC2 -- No NM Yes 
Capri et al, 2017 [16] Claim Mirco No Mean GLM No CCA3 Yes 
Harfouche et al, 2017 [17] 
Harfouche et al, 2017 [17] 
Claim Mirco No Mean -- No CCA3 Yes 
Blumen et al, 2016 [18] Claim Micro No Mean -- No NM No 
Mittmann, et al, 2014 [19] Claim Micro Yes Mean, UNC2 -- No CCA3 Yes 
Wolstenholme et al, 1998 [20] Charge Micro No Mean, UNC2 ANOVA  No CCA3, impute Yes 
Legorreta et al, 1996 [21] Claim Gross No Mean c2, ANOVA No NM4 Yes 
Li et al, 2013 [22] Charge Gross No Mean, UNC2 ANOVA  No NM4 No 
Hoang Lan et al, 2013 [23] Charge Micro No Mean, UNC2 Quantile No CCA3 Yes 
Laas E et al, 2012 [24] Claim Micro No Mean, UNC2 c2, Fisher No Assumption Yes 
Will et al, 2000 [25] UNK1 Micro No Mean -- No NM4 Yes 
Farley et al, 2015 [26] Claim Gross No Mean -- No CCA3 No 
Davari et al, 2013 [27] Charge Micro No Mean, UNC2 -- No CCA3 Yes 
Meneses-Garcia el al, 2012 [28] Charge Micro No Mean, UNC2 -- Yes CCA3 Yes 
Liao et al, 2017 [29] Charge Gross No Mean, UNC2 -- No CCA3 Yes 
Tollestrup et al, 2001 [30] Charge Micro Yes Mean, UNC2 Tobit No NM4 No 
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Subramanian et al, 2011 [31] Claim Micro Yes Mean, UNC2 Two-part No NM4 Yes 
Fireman et al, 1997 [32] Charge Micro Yes Mean, UNC2 OLS No NM4 Yes 
Riley et al, 1995 [33] Claim Micro No Mean, UNC2 -- No NM4 Yes 
Taplin et al, 1995 [34] Charge Gross Yes Mean, UNC2 Multivariate No CCA3 Yes 
UNK1 indicates unknown, UNC2: uncertainty, CCA3 indicates complete case analysis, NM4: not mentioned. 
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Commentary 
Two researchers independently extracted the study characteristics and assessed the 
study quality in this systematic review. If the extracted study characteristics or quality 
scores were different, the two investigators would discuss each item to reach consensus. 
The Drummond checklist was employed to assess the reporting quality of the reviewed 
studies. In addition to employing the Drummond checklist to evaluate the study reporting 
quality, I have also summarised important dimensions of study quality in Table-3 and S2 
Table, including whether costs were based on charges or claims, data collection 
approaches, use of control groups, descriptive analysis, regression model choices, 
censored data analysis, missing data analysis, and timing issues. 
We should be cautious when synthesising the treatment costs in the reviewed studies 
because these costs incurred in different countries. However, this could provide evidence 
from the global perspective that treatment costs of breast cancer generally increased 
with the advancement of the disease stage at diagnosis.  
Blumen et al and Subramanian et al reported that the first-year annual costs of breast 
cancer treatment were higher than the second-year costs. Riley et al divided the period 
from diagnosis to death into four phases and estimated average payments for each 
phase separately. The initial phase consists of the month prior to diagnosis and the 
ensuing six months. The final phase is the last six months of life. The pre-final phase is 
the 12 months immediately preceding the final phase. The time between initial and 
prefinal phases was designated the continuing care phase. The results showed that 
costs in the pre-final phases were more than double those in the continuing care phase 
for each stage. This reflects a period of rising costs before the last months of life.  
Legorreta el al reported that annual costs drop for all clinical stages in the second year 
except stage III, which reflects the high early cost of the treatment of breast cancer 
diagnosed at stage III. Costs did not differ significantly by stage in years 3 and 4. 
However, the numbers were not given in Legorreta et al study and therefore not 
presented in the table below. Also another study by Capri et al reported breast cancer 
costs by time phases. However, the phases were overlapped so this study was not 
presented in the table below.
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Breast cancer treatment costs by time phase and stage (US dollars in 2015) 
Study Time phase Costs by stage 
Stage 0 Stage I/II Stage III Stage IV 
Blumen et al 2016 [18] 1st year 68,456 92,710 146,071 152,048 
 2nd year 12,725 16,872 33,930 54,159 
  In Situ Local Regional Distant 
Subramanian et al 2011 [31] 1st year 29,528 46,768 69,173 100,598 
 2nd year 20,071 26,736 27,447 89,199 
Riley et al 1995 [33]      
Less than 1 year survival Total Not available 47,544 48,093 45,347 
Survived 1 year or more 
 
Initial 18,733 22,679 26,432 32,156 
Continuing 7,907 8,003 8,731 12,444 
Pre-final 20,058 19,192 20,629 27,024 
Final 12,529 10,630 11,698 11,944 
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Chapter 8 
Costs of breast cancer care in England using national patient-level data 
This chapter presents analyses estimating the costs of care among women aged 50 
years and over with a histological diagnosis of early invasive breast cancer in England. 
The study is nested within the National Audit of Breast Cancer in Older Patients 
(NABCOP). I conducted statistical analysis, interpreted the findings, and written the 
manuscript with the supervision from Dr Zia Sadique and Dr Rosa Legood, and support 
from the members of the NABCOP project. All authors approved the final draft prior to 
journal submission and inclusion in the thesis. This paper has been submitted to Value 
in Health. 
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ABSTRACT 
Objectives: This study aimed to use patient-level data to provide up-to-date estimates 
of breast cancer care costs by stage in England, and explore to what extent these costs 
vary across patient age and geographic region.  
Methods: This study identified women aged 50 years and over diagnosed with early 
invasive breast cancer between 01 January 2014 and 31 December 2015 from linked 
cancer registration and routine hospital datasets for England. Cost estimates were 
derived from hospital records in Hospital Episodes Statistics with additional 
chemotherapy and radiotherapy information from the national datasets. We fitted general 
linear regression models to analyse the cost data. The model that best fit the data was 
selected using the model selection criteria of Akaike information criterion.  
Results: 55,662 women with early invasive breast cancer in England were included. The 
generalised linear model with log-gamma distribution fitted the data best. The costs of 
breast cancer care for one year following diagnosis were strongly dependent on stage 
at diagnosis adjusting for other covariates. The estimated average per-patient hospital-
related costs were £5,224 at stage I, £7,617 at stage II, and £13,506 at stage IIIA. Costs 
decreased with increasing age and varied across region, deprivation level, referral 
source, presence of comorbidities, and tumour receptor (ER/PR/HER2) status.  
Conclusions: In England, costs of breast cancer care increased with increasing stage 
of the disease at diagnosis. Variations in breast cancer costs by age and geographic 
region raise questions about the efficiency and consistency of breast cancer treatment 
patterns in England. 
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INTRODUCTION 
Breast cancer is the most commonly diagnosed female cancer in the United Kingdom 
(UK) (62). As in other high-income countries, the number of women living with breast 
cancer in the UK is increasing due to rises in incidence rates (62), increases in the 
number of older women (139), and improved survival (140) as a result of earlier detection 
and treatment improvements. It has been clearly established that earlier diagnosis of 
breast cancer reduces mortality (69), but the cost implications of breast cancer care are 
not well understood (141).  
Stage at diagnosis is an important factor shaping breast cancer treatment pathways. 
Treatment for more advanced breast cancer is more intensive and invasive (105), and 
tends to be associated with greater resource utilisation (107). Costs of breast cancer 
care by stage at diagnosis are important in quantifying the gains from early detection. If 
early treatment lowers costs, this will help offset some costs of interventions that aim to 
achieve earlier diagnosis. In addition, treatment costs by stage would be valuable to 
inform the cost-effectiveness of breast cancer therapies. 
Existing UK data on the costs of breast cancer care by stage at diagnosis were published 
over 20 years ago and are out-of-date (26). Recent National Institute for Health and Care 
Excellence (NICE) appraisals on the cost-effectiveness of breast cancer treatment have 
relied on modelled assumptions (98). This may lead to biased estimates of the full cost 
as there are multi-modal treatments. The consequences of biased estimates are serious 
as, potentially, therapies may be incorrectly rejected or approved by NICE based on cost-
effectiveness evidence. Up-to-date estimates of the costs of breast cancer care by stage 
are required.  
In addition, recent evidence has revealed a differential approach to breast cancer 
management for the older patient in the UK (142), which may explain the poorer survival 
of older women in the UK compared to other European countries (143). Moreover, little 
is known about the geographic variation in costs of breast cancer care across England. 
For example, significant variations in rates and types of immediate breast reconstruction 
procedures were observed among National Health Service (NHS) hospitals in England 
(144). The differences in costs across patient age and region need to be determined.  
In this study, we used patient-level data to estimate the costs of primary breast cancer 
care incurred in the first year after diagnosis, by stage among women aged 50 years and 
over diagnosed in England, and to explore to what extent breast cancer costs vary across 
different patient ages and regions. 
METHODS 
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This study used data from the National Audit of Breast Cancer in Older Patients 
(NABCOP) project, a national clinical audit commissioned by the Healthcare Quality 
Improvement Partnership as part of its National Clinical Audit and Patient Outcomes 
Programme. The details of the national clinical audit were described elsewhere (145). In 
brief, the audit uses anonymised patient-level data from the English and Welsh Cancer 
Registration services, linked to other national datasets to provide information on hospital 
admissions and the use of chemotherapy and radiotherapy. The Office for National 
Statistics (ONS) Death Register provides information on date and cause of death. 
Population and data 
The study population was restricted to women aged 50 years and over with newly 
diagnosed early invasive breast cancer (stages I, II and IIIA) within England over the two 
years between 01 January 2014 and 31 December 2015 and who were treated within 
the NHS. The data was available up to 31 December 2016 so that no patients were 
censored. Patients with advanced (stage IIIb and IV) breast cancer were not included in 
this analysis because bone metastasises information was not available from the 
databases. 
The cancer registration dataset contained patient demographics including age at 
diagnosis, ethnicity, date of diagnosis, and geographic region (cancer alliance). The 19 
cancer alliances were established by NHS England to deliver the national 
recommendations within the NHS Cancer Strategy and to drive local quality 
improvements (146). Tumour characteristics included pathologic stage at diagnosis, 
oestrogen receptor (ER) status, progesterone receptor (PR) status, and human 
epidermal growth factor receptor 2 (HER2) status. ER, PR, and HER2 are breast cancer 
molecular markers that guide the selection of the most appropriate drug therapies and 
are individually recorded as positive, negative, or borderline.  
Hospital admissions were identified from the Hospital Episode Statistics (HES) data. This 
contained date of admission, date of discharge, method of admission, method of 
discharge, date of spell (a continuous period of care in hospital) start, date of spell end, 
procedures undertaken (using the Office of Population Censuses and Surveys (OPCS) 
Classification of Surgical Operations version 4 codes) (147), and Healthcare Resource 
Group (HRG) (148). The HES data were also used as the data source for regional 
deprivation measured as the Index of Multiple Deprivation (IMD) (149) and comorbidity 
burden. Patient IMD scores were grouped into regional quintiles of deprivation, from 
most (=1) to least deprived (=5). Charlson Comorbidity Index was derived from the 
diagnosis fields within HES, which measures the presence of additional medical 
conditions co-occurring with breast cancer (150).  
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The use of chemotherapy and targeted therapy was identified from the Systematic Anti-
Cancer Therapy (SACT) Dataset. The radiotherapy information was obtained from the 
National Radiotherapy Dataset (RTDS). 
Resource use and measurement 
We categorised resource use during the first year of breast cancer care into various 
aspects of the care pathway: 1) diagnosis (triple assessment in a single visit); 2) breast 
procedures (breast surgery (resection, reconstruction, and surgery for lymph node 
involvement), and hospital length of stay); 3) chemotherapy; 4) radiotherapy; 5) 
endocrine therapy; and 6) targeted therapy.  
Patients with suspected breast cancer are recommended to undergo a triple diagnostic 
assessment in a single initial hospital visit, including clinical assessment, imaging 
(ultrasound and/or mammogram), and tissue biopsy (98, 151). We measured the use of 
these diagnostic interventions using dates of imaging and biopsy.  
The types of breast resection surgeries include breast conserving surgery (BCS, removal 
of a part of the breast containing the cancer), mastectomy (removal of all breast), and 
mastectomy with reconstruction. Also, we measured whether or not the patients had 
lymph node involvement and axillary surgeries based on HES data. Axillary surgeries 
covered the activities of sentinel node biopsy and axillary lymph node dissection (98). A 
maximum length of stay is specified for each HRG code. Where the patient length of stay 
during a spell in hospital exceeded that point, we documented the excess hospital bed 
days recorded by the number of overnight admissions.  
We assumed patients received chemotherapy, radiotherapy, or targeted therapy if these 
were reported in SACT and RTDS datasets. Information on endocrine therapy was not 
well captured in SACT so we assumed all ER positive (ER+) or PR positive (PR+) breast 
cancer patients were prescribed endocrine therapy.   
Cost estimation 
Healthcare Resource Groups (HRG) are groups of hospital admissions that have been 
judged to consume a similar level of resource (148). We used unit costs from NHS 
reference costs (152) to assign costs using breast procedure-driven and diagnosis-
driven core HRGs for the continuous inpatient spell. Some patient care episodes may 
have associated high-cost care elements that will generate unbundled HRGs as 
additions to the core HRG, such as chemotherapy, radiotherapy, and other high-cost 
drugs. Only records clearly related to breast cancer care were retained.  
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Excess hospital bed days are reimbursed at a daily cost based on the core spell HRG 
code, which distinguishes between elective and non-elective admissions. With the 
information on admission method, we applied the elective or non-elective excess hospital 
bed day adjustment to the estimated cost where the patient length of stay exceeded the 
maximum specified for a given HRG code. 
We used OPCS procedure codes from SACT and RTDS datasets to assign HRG codes 
to estimate the costs of chemotherapy and radiotherapy. All costs were converted to 
2016 values using the Hospital and Community Health Service Index (153). 
We assumed all ER+/PR+ patients aged over 50 years received an aromatase inhibitor 
(anastrozole) for postmenopausal endocrine therapy as per NICE guidelines (154, 155). 
We obtained the drug cost from the British National Formulary (BNF) (156) to estimate 
the endocrine therapy costs. In addition, we obtained the annual trastuzumab cost per 
patient including administration of treatment and cardiac monitoring from the NICE 
costing report to estimate the targeted therapy costs for HER2+ patients (155). 
Cost analysis 
We fitted generalised linear regression models to estimate the mean costs of primary 
breast cancer care up to one year after diagnosis for women in England. The model 
contained a number of explanatory variables to assess the relationship between cost 
and patient characteristics. Demographic variables included age at diagnosis, ethnicity, 
geographic regions, and IMD. Disease characteristics included disease stage, 
ER/PR/HER2 status, Charlson Comorbidity Index, and referral source (via screening or 
not). We predicted costs of primary breast cancer care by stage at diagnosis for the 
population average, as well as costs for patient subgroups including luminal A (ER+ 
and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2-enriched (ER-, PR-, 
HER2+), and triple negative (ER-, PR-, HER2-) disease based on the St Gallen 
molecular subtype classification (157). As the disease stage may have different effects 
on costs across regions in England, we added the interaction term of stage and region 
in the regression models. 
Using a generalised linear model (GLM) enabled the cost estimates to handle common 
features of health care cost data, such as the substantial skewness with long right-hand 
tails (158), heteroskedastic errors and non-linear responses to covariates (159). 
Typically, a log-link function with a Gamma distribution fitted health care costs well (158). 
However, there was no evidence that this was the dominant form of GLM in terms of 
model fit for cost data applications (160).  
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In this study, we compared the models checking distributions of normal, log-normal, and 
log-gamma respectively. Modified Park Test was conducted to guide the choice of 
distribution reflecting the relationship between variance and mean. The preferred model 
was selected as the one with the minimum Akaike information criterion (AIC) values. We 
reported the marginal effects of explanatory variables on the total costs for the models 
we compared. We conducted the complete case analysis using only data from patients 
for whom all variables involved in the analysis were observed. All statistical analyses 
were undertaken in STATA, version 15.1. 
RESULTS 
The study included 55,662 women aged 50 years and over diagnosed with early invasive 
breast cancer in England between January 2014 and December 2015. The 
characteristics of the women by stage at diagnosis are presented in Table 8-1. The mean 
age was 67 years. The percentages of breast cancer patients diagnosed at stage I, stage 
II, and stage IIIA were 51%, 44%, and 6% respectively. 40% of breast cancer patients 
were screen-detected (found on mammography undertaken by the NHS National Breast 
Cancer Screening Programme), while the other 60% were referred from GP or other 
specialities, or detected due to an emergency presentation (<1%).  
The resource use of breast cancer care is shown in Table 8-2. Determining whether a 
woman had triple diagnostic assessment was not straightforward because many imaging 
and biopsy dates were incomplete in the datasets (145). Adopting a strict set of criteria 
for the analysis of English data suggested that among women diagnosed with early 
invasive breast cancer, and who were not referred from screening, 28% received triple 
assessment in a single visit. If the criteria were relaxed (assuming missing 
mammogram/biopsy dates were the same as the date of biopsy/mammogram 
respectively, incorporating the use of ultrasound where no mammogram was recorded, 
and allowing dates of biopsy and mammogram to differ by one day), the estimated 
proportion of women having a triple diagnostic assessment on the same day was 82%. 
The rates of mastectomy, mastectomy with reconstruction, and axillary lymph node 
dissection increased with more advanced cancer stage at diagnosis, while the rates of 
BCS and sentinel node biopsy decreased with advancing stage. The time spent in 
hospital was short for most breast cancer patients. Most women were typically admitted 
and discharged as day cases, and the excess hospital bed days per patient were 0.06 
days showing increasing trend by advanced stage. In addition, the proportion of patients 
receiving chemotherapy or targeted therapy at stage IIIA was higher than stage I or II. 
The proportion receiving radiotherapy among patients having BCS was 88% compared 
to 41% for patients having mastectomy.  
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The crude costs of first-year breast cancer care among 55,662 patients increased with 
more advanced disease. The subcategories of diagnosis and procedure costs, 
chemotherapy costs, radiotherapy costs, and targeted therapy costs all rose with higher 
stage (Appendix 4). There was some variation in the crude costs of primary breast cancer 
care across cancer alliances, with overall costs typically falling between £5,500 and 
£7,000 (Figure 8-1).  
The results of the compared regression models are shown in Table 8-3, using data from 
22,537 patients for whom all variables involved in the analysis were observed. Missing 
data in HES was negligible with the exception of Charlson Comorbidity Index (3%) while 
the level of incompleteness in Cancer Registry was larger with PR status (51%), HER2 
status (17%), ER status (14%), and ethnicity (6%). The Modified Park Test indicated the 
choice of a gamma distribution and the GLM with log-gamma distribution reported the 
minimum AIC. The regression model showed that the total cost of primary breast cancer 
care increased with advancing stage at diagnosis. Patients diagnosed at stage II incurred 
£2,031 (S.E. £71) more costs and patient at stage IIIA incurred £6,704 (S.E. £256) more 
costs compared to those diagnosed at stage I (p<0.001). 
The regression model indicated that breast cancer costs decreased with increasing age 
(p<0.001), more comorbidities (p<0.001) and higher levels of deprivation (p<0.001). 
Patients with screen-detected cancers incurred lower costs than those diagnosed 
outside screening (p<0.05). There was strong evidence of lower costs in ER/PR+ 
patients and higher costs in HER2+ patients (p<0.001). There was also evidence that 
the costs of primary breast cancer care varied across regions in England (p<0.001). The 
coefficients are presented in Table 8-3 and Appendix 5.  
We predicted the total costs of primary breast cancer care within one year after diagnosis 
using a GLM regression adjusting for patient demographics and tumour characteristics. 
For patient subgroups with different tumour receptor status, the predicted costs of 
primary breast cancer care were £5,082 (S.E. £18) for luminal A patients, £14,439 (S.E. 
£142) for luminal B patients, £18,949 (S.E. £238) for HER2-enriched patients, and 
£7,128 (S.E. £55) for triple-negative patients respectively, all decreasing by age with a 
linear trend (Figure 8-2). With regards to the population average, the adjusted costs of 
breast cancer care within one year after diagnosis in the base case was predicted to be 
£6,815 (S.E. £33) on average for all stages, with £5,224 (S.E. £29) at stage I, £7,617 
(S.E. £49) at stage II, and £13,506 (S.E. £228) at stage IIIA (Figure 8-3).  
DISCUSSION  
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The principle aim of this study was to generate up-to-date estimates of initial early 
invasive breast cancer care costs by stage at diagnosis in England, adjusting for patient 
demographics and tumour characteristics. Our results show that the costs of early breast 
cancer care for the first year after diagnosis increase with more advanced stage at 
diagnosis. The care costs of stage IIIA disease are more than double those of stage I 
disease. The finding is consistent with a global systematic review indicating increased 
breast cancer care costs with advanced stage, in which the treatment costs of breast 
cancer at stage II and stage III were reported to be 32% and 95% higher than stage I on 
average worldwide (141). Previous studies of the treatment costs of breast cancer by 
stage at diagnosis were rather limited due to the poor availability of staging information 
and were predominantly from the US (141). Before our analysis, there was only one very 
dated UK study estimating the costs of breast cancer care using patient-level data, 
reporting that the four-year costs of breast cancer were £6,039 at stage I, £6,749 at stage 
II, and £6,614 at stage III (converted to 2016 values) (26). Our study has therefore 
provided important updated evidence on primary treatment costs for breast cancer by 
stage in England. This is important for future comparative assessment of the cost-
effectiveness of breast cancer screening and therapy interventions.  
Compared to younger breast cancer patients, older patients were shown to incur lower 
costs. This is consistent with the studies that found older patients received fewer 
treatments in the UK. Clinical guidelines emphasise that breast cancer treatment should 
be based on clinical need and fitness for treatment rather than chronological age (98, 
161, 162). Also, Breast Cancer Quality Standards [NICE 2013] explicitly state that 
women, “irrespective of age, are offered surgery, radiotherapy and appropriate systemic 
therapy, unless significant co-morbidity precludes it.” Chronological age should not be a 
dominant factor in the decision to offer a particular treatment. In this study, we attempted 
to control for comorbidity and so the differences across age groups raise questions about 
whether services in the UK have a non-standard approach to breast cancer management 
for older patients (142, 145). The different patterns of resource utilisation might be a 
reason why the survival of older breast cancer patients in the UK and Ireland has been 
reported to be lower compared to other European countries (143). Nonetheless, 
differences in the patterns of care among younger and older patients may arise for 
various reasons, including unmeasured differences in the disease, differences in the 
prevalence and severity of comorbidities and frailty that may contraindicate breast 
cancer treatments (e.g. surgery, chemotherapy or radiotherapy), differences in patient 
preferences and cultural attitudes, and less-involvement of older patients in the decision 
making process (145).  
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We further observed that the costs of breast cancer care varied across regions in 
England, after taking the differences in stage distributions across regions into 
consideration. This is of concern because it suggests different utilisation of breast cancer 
care across England. In the UK, hospitals receive payment based on the procedure types 
according to the NHS National Tariff Payment System (163). The tariffs are defined 
nationally and aligned to promote efficient and high-quality care but the actual cost of 
performing certain procedures can exceed the income that hospitals receive (144). The 
potential for a financial loss may impact on the consideration of the provision of different 
treatment options in hospitals and therefore be reflected by the total costs of breast 
cancer care across cancer alliances in England. An examination of costs could highlight 
areas for review locally and there would probably be a benefit in having benchmark costs 
for particular patient groups for regional audit. In addition to the financial consideration, 
future research could also examine whether the regional variation in costs of breast 
cancer care is related to service provision and/or capacity barriers.  
The advantages of our study population are: (i) it includes all patients with a registered 
diagnosis of early invasive breast cancer in England, diagnosed and treated in an NHS 
trust, (ii) individual patient-based information is available on a large number of variables 
such as socio-demographic factors, comorbidities, and referral source; (iii) information 
on tumour characteristics and treatment received; (iv) linkage between multiple national 
databases.  
Our study is subject to some limitations. We only included breast cancer patients aged 
50 years and over, and limited the follow-up period to one year following diagnosis. Also, 
we excluded patients with metastatic breast cancer and did not consider the costs of 
recurrence. This deserves careful consideration and will underestimate the overall cost 
of care throughout the entire patient pathway. Costs of care in the context of higher stage 
disease are likely to be disproportionately underestimated given the higher risk of 
recurrence.   
We have identified the key methodological differences in cost analysis in the previously 
published global systematic review comparing treatment costs of breast cancer by stage 
across countries (141). Our review showed that most studies used regression 
frameworks but the choice of regression models was rarely justified. Few studies 
described key methodological issues including skewness, zero values, censored data, 
missing data, and the inclusion of control groups to estimate disease-attributable costs 
(141). As no single regression model is dominant in costing analyses, we explored 
different regression models to deal with the skewness issue. In this study, we compared 
regression models with different distributions (normal, log-normal, and log-gamma). 
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Based on the model selection criteria, we evidenced that the GLM with a log-gamma 
distribution fit the data best.  
In addition to skewness, there may also be censoring issues (164). The difference 
between the diagnosis date and the follow-up date is the maximum length of time the 
patients may be followed. If no death occurs in this period, a patient would potentially be 
censored. This type of censoring arising from the planned end of follow-up is known as 
administrative censoring (165). In this study, we used two years of diagnosis and 
included only patients with complete one-year follow up when the study ended on 31 
December 2016. The study population in our analysis therefore includes women 
diagnosed between 01 January 2014 and 31 December 2015 because their follow-up 
information was complete. Future research could explore the impact of censored data, 
for which various methods have been developed (166-168). Moreover, there are many 
missing data in the imaging and biopsy dates due to the incomplete reporting of data. 
We adopted the relaxed criteria as described and assumed 82% of patients had a triple 
diagnostic assessment on the same day. To enable a better understanding of triple 
diagnostic assessment for breast cancer patients, the data completion on imaging and 
biopsy dates needs to be improved. In this study, we conducted complete case analysis 
using only data from 22,537 patients for whom all variables involved in the analysis were 
observed. Missing data in HES was negligible with the exception of Charlson 
Comorbidity Index (3%) while the level of incompleteness in Cancer Registry was larger 
with PR status (51%), HER2 status (17%), ER status (14%), and ethnicity (6%). In further 
research, one could use multiple imputation to impute the missing data (169). Ideally a 
matched control group could be included to estimate breast cancer-attributable costs. 
However, due to the data availability we only included breast cancer patients in this 
study. The inclusion of control groups to estimate disease attributable costs could be the 
direction of future research. 
In conclusion, this study provides up-to-date estimates of breast cancer care costs by 
stage at diagnosis in England. Costs of early invasive (stage I, II and IIIA) breast cancer 
care up to one year after diagnosis increased with advancing stage of the disease at 
diagnosis in England. Variations in breast cancer costs by age and geographic region 
raise questions about the efficiency and consistency of breast cancer treatment patterns 
in England.  
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Tables 
Table 8-1 Cohort characteristics - n (%) unless otherwise stated 
Variables  All  
(n=55,662) 
Stage I  
(n=28,232) 
Stage II 
(n=24,358) 
Stage IIIA 
(n=3,072) 
Age (years) Mean (sd) 67 (11) 66 (10) 69 (12) 66 (11) 
Ethnicity White 49,175 (88%) 24877 (88%) 21559 (89%) 2739 (89%) 
 Asian 1,364 (2%) 633 (2%) 633 (3%) 98 (3%) 
 Black 766 (1%) 304 (1%) 398 (2%) 64 (2%) 
 Other 862 (2%) 444 (2%) 367 (2%) 51 (2%) 
 Unknown 3,495 (6%) 1974 (7%) 1401 (6%) 120 (4%) 
Charlson Comorbidity Index 0 46,078 (83%) 23760 (84%) 19698 (81%) 2620 (85%) 
 1 5,084 (9%) 2477 (9%) 2342 (10%) 265 (9%) 
 2 1,764 (3%) 772 (3%) 889 (4%) 103 (3%) 
 3+ 914 (2%) 392 (1%) 492 (2%) 30 (1%) 
 Unknown 1,822 (3%) 831 (3%) 937 (4%) 54 (2%) 
Index of Multiple Deprivation 1 (most deprived) 7,608 (14%) 3674 (13%) 3468 (14%) 466 (15%) 
 2 9,830 (18%) 4871 (17%) 4410 (18%) 549 (18%) 
 3 11,585 (21%) 5945 (21%) 5011 (21%) 629 (20%) 
 4 13,023 (23%) 6725 (24%) 5600 (23%) 698 (23%) 
 5 (least deprived) 13,616 (24%) 7017 (25%) 5869 (24%) 730 (24%) 
ER status Positive 41,872 (75%) 22109 (78%) 17601 (72%) 2162 (70%) 
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 Negative 6,196 (11%) 2379 (8%) 3316 (14%) 501 (16%) 
 Borderline 22 (<1%) 9 (<1%) 12 (<1%) 1 (<1%) 
 Not performed/unknown 7,572 (14%) 3735 (13%) 3429 (14%) 408 (13%) 
PR status Positive 19,078 (34%) 10114 (36%) 7949 (33%) 1015 (33%) 
 Negative 8,386 (15%) 3515 (12%) 4238 (17%) 633 (21%) 
 Borderline 58 (<1%) 29 (<1%) 27 (<1%) 2 (<1%) 
 Not performed/unknown 28,140 (51%) 14574 (52%) 12144 (50%) 1422 (46%) 
HER2 status Positive 5,494 (10%) 2144 (8%) 2900 (12%) 450 (15%) 
 Negative 38,589 (69%) 20320 (72%) 16234 (67%) 2035 (66%) 
 Borderline 2,296 (4%) 1165 (4%) 988 (4%) 143 (5%) 
 Not performed/unknown 9,283 (17%) 4603 (16%) 4236 (17%) 444 (14%) 
Referral source Screen-detected 22,193 (40%) 15512 (55%) 6072 (25%) 609 (20%) 
 Not screen-detected 33,469 (60%) 12720 (45%) 18286 (75%) 2463 (80%) 
Sd: standard deviation 
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Table 8-2 Resource use – n (%) unless otherwise stated 
Resource use All 
(n=55,662) 
Stage I 
(n=28,232) 
Stage II 
(n=24,358) 
Stage IIIA 
(n=3,072) 
1. Diagnosis 
 
   
Breast ultrasound# 16,548 (30%) 7,394 (26%) 8,157 (33%) 997 (32%) 
Mammography# 21,518 (39%) 10,012 (35%) 10,154 (42%) 1,352 (44%) 
Biopsy# 43,523 (78%) 23,505 (83%) 17,998 (74%) 2,020 (66%) 
2. Breast procedures     
Breast conserving surgery (BCS) 35,718 (64%) 21,962 (78%) 12,753 (52%) 1,003 (33%) 
Mastectomy 12,585 (23%) 3,342 (12%) 7,411 (30%) 1,832 (60%) 
Mastectomy and reconstruction 2,627 (5%) 1,131 (4%) 1,294 (5%) 202 (7%) 
Axillary lymph node dissection 10,044 (18%) 835 (3%) 6,783 (28%) 2,426 (79%) 
Sentinel node biopsy 42,091 (76%) 24,462 (87%) 16,469 (68%) 1,160 (38%) 
Excess hospital bed days – mean (sd) 0.06 (1.24) 0.03 (0.77) 0.09 (1.55) 0.15 (1.81) 
3. Chemotherapy     
Chemotherapy received 9,498 (17%) 2,404 (9%) 5,731 (24%) 1,363 (44%) 
4. Radiotherapy     
Radiotherapy received 37,336 (67%) 19,895 (70%) 14,888 (61%) 2,553 (83%) 
1) Radiotherapy received among patients having BCS 31,290 (88%) 19,181 (87%) 11,196 (88%) 913 (91%) 
2) Radiotherapy received among patients having mastectomy 5,098 (41%) 348 (10%) 3,170 (43%) 1,580 (86%) 
5. Endocrine therapy     
Endocrine therapy received† 42,080 (76%) 22,176 (79%) 17,711 (73%) 2,193 (71%) 
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6. Targeted therapy     
Targeted therapy received 3,606 (6%) 1,250 (4%) 2,002 (8%) 354 (12%) 
#Data on imaging and biopsy dates were incomplete in the datasets. Adopting a strict set of criteria, 28% received triple assessment in a single visit. If 
we assumed missing mammogram/biopsy dates were the same as the date of biopsy/mammogram respectively, incorporated the use of ultrasound 
where mammogram was not reported, and allowed dates of biopsy and mammogram to differ by one day, the estimated proportion of women having 
a triple diagnostic assessment on the same day was 82%.   
†We assumed all ER+/PR+ breast cancer patients received endocrine therapy. 
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Table 8-3 Results for first-year total costs of breast cancer care comparing alternative 
models – coefficient (standard error) 
Variables OLS Log-Normal Log-Gamma 
Stage II 2,002 (79)*** 1,923 (70)*** 2,031 (71)*** 
Stage IIIA 5,995 (159)*** 4,683 (133)*** 6,704 (256)*** 
Age  -160 (4)*** -145 (3)*** -192 (4)*** 
Region *** *** *** 
Region × Stage *** *** *** 
AIC 451,879 451,354 435,161 
N 22,537 
The reference group is patients aged 50 years diagnosed at stage I from North East 
and Cumbria. We adjusted for ethnicity, Charlson Comorbidity Index, Index of Multiple 
Deprivation, ER/PR/HER2 status, and referral source (presented in Appendix 5).  
We conducted the complete case analysis and the sample size was 22,537 patients for 
whom all variables involved in the analysis were observed. Missing data in HES was 
negligible with the exception of Charlson Comorbidity Index (3%) while the level of 
incompleteness in Cancer Registry was larger with PR status (51%), HER2 status 
(17%), ER status (14%), and ethnicity (6%). 
***p<0.001   
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Figures 
 
Figure 8-1 Crude costs of first-year primary breast cancer care by region 
Regions are numbered from 1 to 19 for North East and Cumbria (6.2% of breast cancer 
patients diagnosed in this region), Lancashire and South Cumbria (2.8%), Greater 
Manchester (4.9%), West Yorkshire (4.3%), Humber, Coast and Vale (2.8%), South 
Yorkshire, Bassetlaw, North Derby (3.2%), Cheshire and Merseyside (5.1%), West 
Midlands (10.7%), East Midlands (7.2%), East of England (11.7%), Peninsula (3.9%), 
Somerset, Wiltshire, Avon & Gloucestershire (5.4%), Wessex (5.8%), Thames Valley 
(4%), Surrey and Sussex (6.3%), Kent and Medway (3.7%), West London (5.4%), South 
East London (2.2%), and North Central and East London (4.5%). The vertical lines at the 
top are 95% confidence intervals around the total costs. Alliance 18 is South East London. 
The variation in total costs of breast cancer care across cancer alliances was driven by 
all component costs according to one-way analysis of variance (ANOVA) results. 
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Figure 8-2 Predicted costs of first-year primary breast cancer care by patient 
subgroups 
For patient subgroups with different tumour receptor status, the predicted average costs 
of primary breast cancer care were £5,082 (S.E. £18) for luminal A patients, £14,439 
(S.E. £142) for luminal B patients, £18,949 (S.E. £238) for HER2-enriched patients, and 
£7,128 (S.E. £55) for triple-negative patients respectively, all decreasing by age with a 
linear trend. 
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Figure 8-3 Predicted population average costs of first-year primary breast cancer care 
by stage at diagnosis 
We predicted the first-year costs of breast cancer treatment by stage at diagnosis 
adjusting for age, ethnicity, Charlson Comorbidity Index, Index of Multiple Deprivation, 
tumour receptor (ER/PR/HER2) status, referral source, and regions. The predicted costs 
were £5,224 (S.E. £29) at stage I, £7,617 (S.E. £49) at stage II, and £13,506 (S.E. £228) 
at stage IIIA for the population average. The vertical lines at the top are 95% confidence 
intervals around the total costs. 
F-test showed p-value <0.001.    
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Chapter 9 Discussion 
In this discussion chapter, I first summarise the key findings of my thesis and the 
implications for policy and practice. Also I reflect on the methodology for breast cancer 
modelling and costing. Then I discuss the limitations of my thesis and identify the areas 
for future research. Finally, I draw a number of concluding comments.  
9.1 Key findings 
The first objective of my thesis was to review the literature and summarise the existing 
economic evidence on breast cancer screening in LMICs and breast cancer genetic 
testing in HICs (Chapter 3). Although some studies have been performed in recent years, 
the cost-effectiveness evidence on the ongoing breast cancer screening pilot 
programmes in urban and rural China is lacking. This led me to the second objective of 
this thesis, to conduct economic evaluations of breast cancer screening programmes in 
urban and rural China.  
With regards to economic evidence on breast cancer genetic testing, there is only a 
recent small Norwegian study (535 patients) showing the cost-effectiveness of BRCA-
testing in all breast cancer patients and cascade testing of relatives of index cases based 
on a decision tree model (21). This led me to the third objective of this thesis, to evaluate 
the cost-effectiveness of multigene testing all breast cancer patients and cascade testing 
the relatives of mutation carriers in the UK and US which is both broader in scope in 
terms of gene types and prevention options, as well as draws on a much larger sample-
size of population-based breast cancer patients. 
The second objective of the thesis was to evaluate the cost-effectiveness of Chinese 
urban and rural breast cancer screening pilot programmes compared to no screening. 
The urban programme screens high-risk women (with a questionnaire-generated risk 
score greater than the threshold risk) by ultrasound and/followed by mammography (16). 
I developed a Markov model to estimate the cost-effectiveness, showing that the risk-
based screening in urban China was economically attractive with an ICER of 
US$ 6,645/QALY, well below the threshold of US$ 23,050/QALY (35, 36). One-way and 
probabilistic sensitivity analyses demonstrated that the results were robust. In the 
exploration of various scenarios, screening every 3 years was the most cost-effective 
strategy in urban China (Chapter 4).  
The rural programme screened the general population with clinical breast examination 
coupled with ultrasound as the primary tool (17). The baseline results show that the rural 
population-based breast cancer screening is cost-effective with an ICER of $6,879/QALY. 
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However, the cost-effectiveness result is very uncertain in the sensitivity analysis and 
rural breast screening among the general population could potentially harm women’s 
health due to false positives with the current screening tool. The sensitivity analysis 
identified utility loss from false positives as the factor that most influenced the results. 
The lower limit of disutility from false positives at which rural breast cancer screening 
programme would remain cost-effective at the willingness-to-pay threshold was 0.029 
QALYs in the screening year, corresponding to 14.5% quality of life decrement of full 
health over 0.2 years (Chapter 5). 
There are a few reasons that could explain the apparent discrepancies in conclusions 
between breast cancer screening programmes in urban and rural China. Firstly, the 
incidence rate of breast cancer in rural China is significantly lower than that in urban 
China (17.0 vs. 34.3 per 100,000 person-years in 2009) (138). The lower incidence rate 
results in fewer breast cancer patients detected, thus challenging the utility and cost-
effectiveness of screening programmes in such settings. Secondly, screening by clinical 
breast examination and ultrasound as the primary tool may not be suitable in the rural 
breast cancer screening programme. Although clinical breast examination has been 
used in low resource settings, there are no randomised trials providing any evidence of 
whether clinical breast examination could lead to reductions in breast cancer mortality 
(170). Also, whilst ultrasound may be better at detecting small invasive breast cancers 
in women with dense breasts (82-86), it is usually recommended as an adjunct to 
mammography screening among women at higher risk for breast cancer rather than as 
a primary screening method for women at average risk (171-174). This leads to lower 
screening sensitivity and specificity (175), thus against the cost-effectiveness of breast 
cancer screening among rural Chinese women. Thirdly, the urban programme deploys 
a risk-stratified screening strategy while the rural programme uses a ‘one-size-fits-all’ 
screening approach without individual variation in risk taken into consideration. Tailoring 
screening to an individual’s risk level could improve the efficiency of the screening and 
reduce its adverse consequences (176-179). Whilst risk-based screening requires 
additional costs of assessing the risk of all women in the urban screening programme, 
these could be offset by avoiding some of the costs of biopsy confirmation and disutility 
from false-positives, thus maintaining the cost-effectiveness of the urban breast cancer 
screening program. 
The third objective was to evaluate the cost-effectiveness of offering multi-gene testing 
to all breast cancer patients compared to the current practice of family-history/clinical-
criteria based genetic (BRCA)-testing in the UK and US. I obtained data on family history 
from 11,836 population-based BC patients (regardless of family history) recruited to four 
large research studies in the UK, US, and Australia. I developed a microsimulation model 
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which could capture individual heterogeneity to estimate the lifetime cost, effects, and 
cost-effectiveness of unselected BRCA1/BRCA2/PALB2 testing for all breast cancer 
patients, compared with the current family-history/clinical-criteria based BRCA-testing. 
The ICERs from a payer perspective (UK £10,646/QALY or US $65,661/QALY) and 
societal perspective (UK £7,216/QALY or US $61,618 QALY) were well below the cost-
effectiveness thresholds in the UK and US, and the results were robust to alternative 
assumptions considered in extensive sensitivity analyses. The scenario analysis 
reconfirms the cost-effectiveness of lower (70%) uptake rates of genetic testing by breast 
cancer patients and their relatives. One year’s unselected multi-gene testing can prevent 
2,101 breast cancer/ovarian cancer-cases and 633 deaths in the UK; and 9,733 breast 
cancer/ovarian cancer-cases and 2,406 deaths in the US. Correspondingly, 8 UK/35 US 
excess heart-disease deaths occur annually. Unselected multi-gene testing provides 
huge opportunities for preventing breast cancer/ovarian cancer cases and deaths. This 
conclusion can therefore provide a basis for changing the current guidelines and policy 
to expand genetic testing to all breast cancer patients (Chapter 6).  
The fourth objective of the thesis was to review the literature on treatment costs of breast 
cancer by stage at diagnosis using patient-level data across countries at different levels 
of socio-economic development and to identify key methodological differences in costing 
approaches. Overall, the evidence suggested that the treatment costs of breast cancer 
generally increased with the advancement of the disease stage at diagnosis. Also, this 
published systematic review contributed to the scientific body of knowledge on the 
methodology of breast cancer cost analysis. Most existing studies on costs of breast 
cancer care used regression frameworks but the choice of regression models was rarely 
justified. Few studies described key methodological issues including skewness, zero 
values, censored data, missing data, and the inclusion of control groups to estimate 
disease-attributable costs (Chapter 7). From the literature, the evidence on breast cancer 
treatment costs by stage based on patient-level data in the UK is very limited and out-of-
date, published 20 years ago (26). This leads me to the fifth objective to use patient-level 
data to estimate the costs of breast cancer treatment in the UK. 
I obtained anonymised patient-level data of 55,662 breast cancer patients from the 
National Audit of Breast Cancer in Older Patients (NABCOP) project. Patient information 
is available on a large number of variables such as tumour characteristics, socio-
demographic factors, and treatment regimens. I compared different data distributions in 
the regression model to deal with the cost data issues and the model that best fit the 
data was selected for the base case analysis based on the model selection criteria. The 
results show that the costs of breast cancer care increase with more advanced stage at 
diagnosis. The predicted costs were £5,224 at stage I, £7,617 at stage II, and £13,506 
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at stage IIIA. This has confirmed the findings in the literature about the significant cost 
savings if patients with breast cancer are detected earlier. Also breast cancer costs vary 
by age and region, raising questions about the efficiency and consistency of breast 
cancer treatment patterns in England. Due to the limited data availability, I only obtained 
the first-year treatment information of breast cancer patients and cannot estimate the 
total costs of breast cancer care from diagnosis to death. Therefore, the cost estimates 
of breast cancer care up to one year after diagnosis using patient-level data did not feed 
into the economic modelling of genetic testing (Chapter 6) in my thesis. I discussed this 
in the limitation section (section 9.4).  
9.2 Implications for policy and practice 
9.2.1 Discrepancy in breast cancer screening between urban and rural China 
My studies on the cost-effectiveness of breast cancer screening in rural and urban China 
can inform whether we should continue the current breast screening policy in China. 
Risk-based breast cancer screening by ultrasound and/followed by mammography in 
urban China is economically attractive, while general population-based breast cancer 
screening with clinical breast examination coupled with ultrasound as the primary tool in 
rural China reports uncertain cost-effectiveness and could potentially do harm to 
women’s health due to false positives.  
In urban China, several challenges can be raised by the implementation of a risk-based 
screening programme, such as preparing and training the workforce, ensuring equitable 
access, and having regulatory approvals (180). In China, patients need to pay on 
average 34% of total medical costs (181); this can limit access to medical treatment for 
some women who have been diagnosed with breast cancer. Also, not offering screening 
to women at lower risk may not be acceptable (182) because women have been 
encouraged to see screening as universally beneficial and reduction in screening could 
be seen as service rationing (183). It is important to engage the public in decisions about 
screening programme modification and to communicate clearly the benefits and harms 
of screening.  
In rural China with such low breast cancer incidence, risk-based breast screening could 
potentially be an option to screen high-risk women instead of the general population. In 
addition, priority should be given to downstaging by ensuring symptomatic women have 
proper access to diagnosis and treatment at an early stage, as this will lead to reductions 
in mortality from breast cancer without the usual harms associated with breast screening. 
In rural China, breast cancer is diagnosed at a later stage (67) and thus survival is poorer 
(68). More cost-effective approaches should be implemented to reduce delays in 
diagnosis and treatment and thus improve the prognosis of breast cancer among rural 
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Chinese women. Downstaging is likely to be more cost-effective than screening in rural 
China because the resources will be concentrated on women with breast symptoms 
instead of the general population. Also, in order to cope with a large number of screen-
detected suspicious lesions, a cancer care system must be well-organised enough and 
able to deal appropriately with the symptomatic disease (184). Hence, developing 
culturally-sensitive and cost-effective strategies to promote early diagnosis and 
treatment of clinically detectable women, rather than screening asymptomatic women, 
should be regarded as a priority in rural China. 
9.2.2 Expanding gene testing to all breast cancer patients 
Unselected high-risk multigene-testing for all breast cancer patients is extremely cost-
effective compared with the current family-history/clinical-criteria BRCA testing for UK 
and US health systems. Newly diagnosed breast cancer patients with identified 
mutations can opt for CPM to reduce the contralateral breast cancer risk. They may also 
become eligible for novel drugs like PARP-inhibitors and other precision-medicine based 
therapeutics through clinical trials (185). In addition, unaffected mutation carriers can 
choose different options to reduce their risks of developing breast cancer or ovarian 
cancer. We recommend changing the current policy to expand genetic testing to all 
breast cancer patients in the UK and US settings.  
Existing genetic-counselling services running through high-risk cancer-genetics clinics 
do not have the resources or manpower to deliver unselected genetic-testing for all 
breast cancer patients due to the large numbers diagnosed annually. Hence, newer 
‘context-specific’ delivery models will be needed for implementing this approach. This 
may require pre-test counselling to be undertaken by non-genetic clinicians who will need 
to be trained for this. This approach of ‘mainstreaming’ genetic-counselling and testing 
has recently been successfully implemented in ovarian cancer treatment pathways (186, 
187). Oncologists, surgeons and clinical nurse-specialists have provided pre-test 
counselling and genetic-testing (186, 187), with genetic-services focusing on post-test 
counselling and support for women carrying pathogenic-variants. A similar approach 
could work for breast cancer patients too. Examples of other delivery options include a 
genetics-service coordinated nurse-led model (188), a Genetics-Embedded-Model 
(genetics clinician/counsellor embedded in the cancer clinic) (189, 190) and Telephone-
counselling (191-193) or Tele-genetics services (194) for genetic-counselling and testing. 
Going forward, most clinicians practicing medicine will need an increased understanding 
of genetics and the ability to counsel patients about this (96, 195). Appropriate clinical 
decision-support tools can facilitate this transformation. Another potential bottleneck to 
address is laboratory infrastructure to manage increased sample throughput. The 
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outcomes of various genetic-testing implementation pathways for breast cancer patients 
could be evaluated. 
9.2.3 Early diagnosis of breast cancer and different treatment patterns  
In England, costs of early invasive breast cancer care increased with advancing stage of 
the disease at diagnosis. Considerable cost savings could be made if patients with breast 
cancer were detected and treated earlier. This also supports the future assessment of 
the cost-effectiveness of breast cancer screening interventions. 
My study revealed a non-standard approach to breast cancer management for patients 
across age and regions. Clinical guidelines emphasise that breast cancer treatment 
should be based on clinical need and fitness for treatment rather than chronological age 
(98, 161, 162). Chronological age should not be a dominant factor in the decision to offer 
a particular treatment. In England, older patients were shown to incur lower costs of 
breast cancer care than younger patients. The different patterns of resource utilisation 
might be a reason why the survival of older breast cancer patients in the UK and Ireland 
was particularly low compared to other European countries (143). Also, costs of breast 
cancer care varied across regions within England, raising questions about the efficiency 
and consistency of breast cancer treatment patterns in England. Nonetheless, 
differences in the patterns of care among patients may arise for various reasons, 
including unmeasured differences in the disease nature, differences in the prevalence 
and severity of comorbidities and frailty that may contraindicate breast cancer treatments 
(e.g. surgery, chemotherapy or radiotherapy), differences in patient preferences and 
cultural attitudes, and different levels of involvement in the decision making process 
(145). These factors need to be taken into consideration when we explore unequal 
access to breast cancer care among patients in England.  
9.3 Reflection on methodology for modelling and costing  
9.3.1 Markov model of breast cancer screening 
There was only one previously published Markov model of breast cancer screening 
specifically for Chinese women (196). This model assumed that breast cancer-related 
deaths only occurred among patients in stage IV, which may lead to biased transition 
probabilities. I adapted this model to make the model estimates more reliable in China. 
In my model, patients at different stages could die from breast cancer with different 
fatality rates. I modelled the cost-effectiveness of breast cancer screening compared with 
no screening, where breast cancer in the non-screening arm can only be diagnosed on 
presentation of symptoms. One issue is the lack of data on transition probabilities for 
China. Transition probabilities data are generally difficult to get and in this study I 
obtained the data from the literature and explored the uncertainty in the sensitivity 
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analyses. In addition, the probabilities of presenting symptoms by stage were not 
available from the literature. To help with this problem, I estimated the probability of 
presenting symptoms by stage via model calibration, using the distribution of incidence 
cases reported in an unscreened population based on the Chinese Cancer Registry 
Annual Report 2012 (138). The predicted breast cancer incidence by my Markov model 
fits with the real disease incidence in China. Therefore, the updated breast cancer 
screening model in my thesis reflects the disease natural history better and the transition 
probabilities are more applicable to the Chinese population (Chapter 4 & 5). However, I 
assumed the probabilities of presenting symptoms by stage in rural China were the same 
as the values in urban China, which may limit the accurate estimates of transition 
probabilities of disease progression in rural areas. Another limitation of my model is that 
transitions across more than one stage within one year were not allowed with an annual 
transition. Although breast tumours grow gradually, the progression could be sufficiently 
rapid so tumours progress through more than one stage within a year. Not allowing 
transitions across more than one stage in the presence of rapidly progressing tumours 
indicates the assumption of a slower progression rate in the model. This could lead to 
biased estimates of transition probabilities and deserves careful considerations.  
9.3.2 Microsimulation model of breast cancer genetic testing  
There was only one Norwegian study (535 patients) showing the cost-effectiveness of 
BRCA-testing all breast cancer patients and cascade testing of relatives of index cases 
(21). They used a decision tree to compare testing all breast cancer patients with the 
traditional family history-based approach, which was limited by not allowing the patient 
variability in age and prevention options. In my thesis I developed an individual-level 
microsimulation model of breast cancer genetic testing from scratch which has a few 
advantages over cohort-based models.  
Microsimulation models permit individual differences in age and gene mutation type 
among breast cancer patients and relatives of index cases, which could impact the 
transition probabilities in the pathways through the model. I used the very large trial 
numbers in the microsimulation model to get robust and consistent results. In the 
microsimulation model, I ran 269,884 simulations (54,483 patients and 215,401 relatives) 
for the UK analysis and 1,236,220 simulations (242,463 patients and 993,757 relatives) 
for the US analysis. Gene types and age were assigned to breast cancer patients and 
relatives based on the corresponding distributions. In addition, the microsimulation 
model can track individual patient history if the memory of events impacts future cycles. 
In my model, breast cancer patients with BRCA/PALB2 mutations can choose CPM to 
reduce contralateral breast cancer risk and RRSO (BRCA only) to reduce ovarian cancer 
risk. Among relatives of index cases, unaffected BRCA/PALB2 mutation carriers can 
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choose RRM/chemoprevention to reduce breast cancer risk and RRSO (BRCA only) to 
reduce ovarian cancer risk. These risk-reducing options can be tracked in the 
microsimulation model, impacting their probability of developing breast cancer or ovarian 
cancer in future cycles.  
9.3.3 Model validation 
 
In Chapter 4 and Chapter 5, I adapted Markov models using data from the screening 
programmes that provided costs and quality of life of breast cancer patients by stage at 
diagnosis to inform the process of breast cancer screening. In Chapter 6, I established 
the microsimulation model using data from four large research studies that provided age 
and family history data of breast cancer patients to inform the process of unselected 
genetic testing and clinical-criteria/family history based testing. Internal Validation of the 
models was undertaken through a process of Descriptive Validity, Technical Validity and 
Face Validity (197). 
Descriptive Validity- the models provide adequate pictures of clinical reality. The models 
cover all relevant aspects and do not miss any aspects that could alter its results and 
conclusions significantly. The data and the model structures were reviewed by 
national/international breast cancer clinical, epidemiological, and health economic 
experts to provide adequate pictures of models of breast cancer screening and genetic 
testing.    
Technical Validity/Verification- I undertook a process of internal validation to ensure the 
model’s proper functioning. This included debugging where needed and calibration to 
check the consistency of the model with observable data. Also in Chapter 6, I used the 
very large trial numbers in the microsimulation model to get robust and consistent results. 
In the microsimulation model, I run 269,884 simulations (54,483 patients and 215,401 
relatives) for the UK analysis and 1,236,220 simulations (242,463 patients and 993,757 
relatives) for the US analysis. Gene types and ages were assigned to breast cancer 
patients and relatives based on the corresponding distributions. 
The model’s technical functioning was also tested by extensive sensitivity analyses. 
Extreme values of the input variables were used, and the model’s actual outputs were 
compared with expected outcomes. In Chapter 4 and Chapter 5, when assuming zero 
uptake rate of screening, the intervention arm and the comparator arm calculated the 
same outcomes. In Chapter 6, when assuming zero uptake rate of genetic testing, the 
unselecting testing arm and the clinical-criteria/family history based testing arm 
calculated the same outcomes. Moreover, I examined the individual impact on results of 
each parameter in the one-way sensitivity analysis and explored various scenarios such 
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as less frequent screening and lower uptake rate of treatment in the breast cancer 
screening models, and increased counselling costs, no HRT compliance after RRSO, 
increased age for RRM/RRSO in the genetic testing microsimulation model. The 
direction of changes in health effects and/or costs were all in line with expectations.  
Face Validity was confirmed through the model producing outputs that were consistent 
with the theoretical basis of the disease and the medical interventions undertaken. 
A limitation of model validation is that the predictive validity of breast cancer screening 
and genetic testing models was not able to be tested, which relates the modelling results 
to real-life outcomes. Up to now there have been no available outcomes reported from 
the urban or rural screening programme in China. Also the real-life outcomes of 
unselected multi-gene testing for all breast cancer patients in the UK and US are 
unknown. Tests of predictive validity are only possible if the modelled situation is 
observable and measurable.   
9.3.4 Costing methodology 
Health care cost data typically have some key statistical features. First, the distributions 
display substantial skewness usually with long right-hand tails. Second, their 
distributions may have a substantial point mass at zero (158). Moreover, there are issues 
of heteroskedastic errors and non-linear responses to covariates due to the implicit 
underlying data-generating process (159). Although ordinary least squares (OLS) has 
been widely used in regression models, it ignores the skewness and therefore is not 
appropriate in cost analysis. One classic econometric approach to deal with skewness 
is logarithmic transforming the data to an approximately normal distribution. However, 
transforming the data is not favoured due to back-transformation problems (60). The 
arithmetic mean cost is the parameter of interest, and retransforming costs to the natural 
scale requires difficult calculations, particularly when there is heteroskedasticity (198).  
I used a generalised linear model (GLM) to analyse the cost data. This allowed me to 
model costs directly on the scale of interest and allowed for forms of heteroskedasticity 
(199). GLMs comprise a link function, which determines the relationship between a linear 
index of covariates and the mean, and a distribution function, which determines the 
relationship between the mean and the variance (198). Typically, a log-link function with 
a Gamma distribution fits the health care costs well (158). However, there is no evidence 
that this is the dominant form of GLM in terms of model fit for cost data applications (160). 
I compared the models checking distributions of normal, log-normal, and log-gamma 
respectively. The model that best fitted the data would be selected using the model 
selection criteria of Akaike information criterion (AIC). AIC estimates the relative amount 
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of information lost by a given model. The preferred model is the one with the minimum 
AIC values.  
Based on the systematic review in Chapter 7 which identified the methodological 
differences in breast cancer costing approaches, most studies used regression 
frameworks but the choice of regression models was rarely justified. Few studies 
described key methodological issues including skewness, zero values, censored data, 
missing data, and the inclusion of control groups to estimate disease-attributable costs. 
This suggests that methodological issues should be better handled and properly 
described in future costing studies. My study has justified the choice of regression 
models and provided evidence to further understanding of cost analysis methodology to 
deal with data issues. In further research, I could use multiple imputation to impute the 
missing data.  
9.4 Limitations 
The first limitation is the uncertainty of disutility from false-positive breast cancer 
screening results among Chinese women. Although the concerns about false-positive 
breast cancer screening are justified, the decrements in health-related quality of life are 
still controversial (122). Some argue that pathologically elevate levels of distress and 
anxiety are not apparent (200), but the relatively small number of studies means that the 
long-term effects of false-positive breast cancer screening are still unknown (200). In this 
analysis, I used the estimate from the UK studies (132, 133) which might bias the cost-
effectiveness results of breast cancer screening in China. If we were to assume the false-
positive screening results do not affect a woman’s quality of life, the results in urban 
China proved to be robust while breast cancer screening in rural China would achieve 
an ICER below the threshold. This deserves careful consideration and further research 
on disutility from false-positives in China is required to reduce uncertainty.  In addition, 
duration between getting a positive screening result and undertaking a biopsy test for 
diagnostic confirmation is very likely to be much shorter than one year. As the relevant 
data is lacking in China, future research needs to be conducted to estimate the duration 
between false-positive screening results and biopsy tests, as well as to explore the 
fluctuations in the quality of life in terms of timing of assessment after false-positive 
results.   
Second, there are different types of breast cancer and therefore the biology of breast 
cancer may be heterogeneous in the natural history Markov model. Some tumours are 
detected late because they are aggressive and fast-growing. Others may spread before 
screen-detection is possible, in which case early detection may not improve disease 
prognosis. In addition, some tumours may grow so slowly (or even not at all) that if they 
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went undetected they would never cause symptoms or people would die from another 
cause before breast cancer presented. The problem is that when these types of cancer 
are diagnosed early, it is very difficult to tell the potentially harmful ones from the 
harmless ones, and therefore everyone is then offered treatment. Ideally, RCTs should 
be conducted to evaluate the benefits and harms of the breast cancer screening 
programmes and the time horizon should be long enough to capture differences in long-
term health outcomes including mortality. To our knowledge no such RCTs have been 
conducted or are ongoing in rural China. Therefore, in the absence of evidence from 
RCTs, I adopted a Markov natural history model to evaluate the cost-effectiveness of 
breast cancer screening in China. If more data on the biology of breast cancer and 
disease progression are available, model structure uncertainty could be explored in 
future studies with the heterogeneous breast cancer biology taken into consideration.  
Third, the thesis is limited by the lack of data on the differences in the treatment costs of 
breast cancer between Chinese urban and rural patients. I obtained the costs of breast 
cancer treatment by stage at diagnosis from a study enrolling 2,746 patients from 37 
hospitals across 13 provinces in China. However, the treatment costs incurred by rural 
and urban patients with breast cancer may be different. Rural residents in China with 
severe diseases tend to seek the secondary or tertiary level of medical treatment in urban 
hospitals (201). Since they usually need to travel further to reach the hospitals, the direct 
non-medical costs including transport costs might be underestimated in this study. In 
addition, the rural-urban differences have been observed in the choice of neo-adjuvant 
chemotherapy and surgical procedures (202). Rural patients with breast cancer also tend 
to have worse adherence to adjuvant treatment, which is strongly associated with 
recurrence (203). These factors could result in differences in the direct medical costs 
between urban and rural patients. The sensitivity analysis proves that the results are 
quite robust when the treatment costs are varied up and down by 30%, but the impact of 
cost variations on the overall results could be further explored if more detailed evidence 
is available on the treatment costs of urban and rural patients.  
Fourth, the baseline microsimulation model of genetic testing assumes all breast cancer 
women and unaffected relatives undergo genetic-testing. While very-high (up-to 98%) 
genetic-testing rates are reported in unselected genetic-testing at ovarian cancer 
diagnosis, corresponding genetic-testing uptake data in unselected breast cancer 
patients are not well-established. To explore the model structure uncertainty, I conducted 
a scenario analysis at lower (70%) uptake rates and the results reconfirmed the cost-
effectiveness of genetic testing in breast cancer patients and relatives of index cases.  
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Fifth, I used three times the Chinese GDP per capita ($23,050/QALY) as the China WTP 
threshold recommended by the WHO (35), £30,000/QALY as the UK WTP threshold 
recommended by the NICE guideline (30), and $100,000/QALY as the US WTP often 
cited in the literature (34). However, these thresholds have little theoretical justification. 
WTP thresholds should be based on estimates of the forgone benefit associated with 
alternative priorities which consequently cannot be implemented as a result of the 
commitment of resources to an alternative. Woods et al. estimated WTP thresholds for 
a number of countries based on recent empirical estimates of foregone benefits and 
internal income elasticities of the value of health (204). The WTP thresholds were 
reported to be $7,957/QALY in China, $18,607/QALY in the UK, and $40,112/QALY in 
the US respectively, which are much lower than those posited by WHO or NICE. 
Therefore, the cost-effectiveness of breast cancer screening and genetic testing 
strategies evaluated in my thesis may be overestimated and might be ruled out based 
on these thresholds. However, Woods suggested these WTP thresholds are not 
definitive; rather, further research needs to be provoked in the area of crucial policy 
importance and outlines how more robust estimates could be generated. In addition, 
even if estimated accurately, WTP thresholds do not provide information on affordability, 
budget impact or the feasibility of implementation. Although cost-effectiveness ratios are 
informative in assessing value for money, WTP thresholds should therefore not be used 
alone as a decisions rule for priority setting. Local policy context needs to be considered 
(205) and multiple-criteria decision analysis could be applied to inform decision-making 
(206).  
Lastly, the cost estimates of breast cancer care using patient-level data in Chapter 8 did 
not feed into the economic modelling of genetic testing in Chapter 9. Ideally, the 
estimated breast cancer costs based on patient-level would inform the model inputs with 
sampling uncertainty captured. Unfortunately, due to limited data availability, I only 
obtained treatment information of breast cancer patients in the first year after diagnosis 
and therefore the full costs of breast cancer care cannot be estimated from diagnosis 
until death. Instead, I estimated the total costs of breast cancer care based on the clinical 
guidelines as the input to the economic model. Also I varied the cost estimates by +/-30% 
in the one-way sensitivity analysis and specified the costs as a Gamma distribution in 
the probabilistic sensitivity analysis to explore the uncertainty. If long-term treatment 
information was available among breast cancer patients, I would be able to compare 
estimating breast cancer care costs using patient-level routine data with using clinical 
guidelines. Also I would explore whether using cost estimates with patient-level routine 
data would change the cost-effectiveness results in the economic evaluation. In addition, 
treatment costs could ideally be split between initial treatment costs and recurrent costs. 
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However, in this analysis we were not able to distinguish recurrent costs from initial 
treatment costs. This could be a limitation of this study and deserves careful 
considerations. 
9.5 Areas of further research 
9.5.1 Disutility from false-positives to inform the economic evaluation of breast 
cancer screening 
The current economic evaluation of breast cancer screening in China is limited by the 
lack of data on disutility from false-positive screening results among Chinese women. 
Although I explored the uncertainty in the one-way and probabilistic sensitivity analyses, 
the real effects of false-positive breast cancer screening on Chinese women’s health are 
still unknown (122, 200). Further studies could be undertaken to explore the decrements 
in health-related quality of life due to false-positive breast cancer screening among 
Chinese women to reduce uncertainty. I would use EQ-5D questionnaires to measure 
the quality of life among Chinese women attending breast cancer screening with positive 
results and explore the durations between false-positive screening results and biopsy 
tests for diagnostic confirmation. As the timepoints of assessment are likely to influence  
the overall health-related quality of life decrements, I would be able to capture the 
fluctuation in the quality of life and the duration of disutility from false-positives to get 
more robust results. 
9.5.2 Modelling on unselected gene testing to patients in China 
Unselected multi-gene testing for all breast cancer patients can substantially reduce 
future breast cancer-&-ovarian cancer cases and deaths compared with the current 
clinical-strategy. My analysis suggests that an unselected-testing strategy is cost-
effective for UK and US health-systems from both payer and societal perspectives. This 
provides a basis for expanding the study population to other countries. In China, the 
effectiveness and cost-effectiveness of unselected multi-gene testing for breast cancer 
patients have never been evaluated before. I could for the first time provide the economic 
evidence on unselected multigene testing among Chinese women diagnosed with breast 
cancer. 
I have already developed a microsimulation model for the cost-effectiveness of multi-
gene genetic testing in the UK/USA. The model would be adjusted/adapted for the 
Chinese evaluation by using Chinese data on parameter inputs supplemented with 
appropriate data from the international literature. As an example, Chinese family 
structures vary significantly from the UK especially reflecting the one-child policy in China 
(which has now been changed). I would utilise Chinese national statistics to explore the 
numbers of female relatives that would need to be tested as this would be very different 
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from the UK setting. Also we have got access to the Chinese Urban Basic Medical 
Insurance Database. I would use the ‘big data’ to analyse the treatment costs of breast 
cancer in China and explore the regional variations in costs.  
Uncertainties would be explored through extensive one-way and probabilistic sensitivity 
analysis. I would also explore the cost-effectiveness at different genetic testing costs and 
the threshold to which the cost of genetic testing must fall in order for the policy to be 
cost-effective. As the willingness to pay (WTP) threshold is not clear in China, I would 
explore the probability of genetically testing all breast cancer patients being cost-effective 
across a range of different WTP thresholds. All these analyses would be conducted 
across regions to explore differences with regional variation. In addition, I would conduct 
the budget impact analysis to estimate the likely change in expenditures to the budget 
holder resulting from offering genetic testing to breast cancer patients. This modelling 
work would inform the potential cost-effectiveness of genetic testing for breast cancer in 
China and also provide much needed direction on further research that needs to be 
conducted in this field and the factors driving the uncertainty. 
9.5.3 Further analysis of breast cancer costs 
As I only obtained the first-year treatment information of breast cancer patients from the 
National Audit of Breast Cancer in Older Patients (NABCOP) project, the cost estimates 
of breast cancer care using patient-level data (Chapter 8) did not feed into the economic 
modelling of genetic testing (Chapter 6) in my thesis. If long-term treatment information 
is available in the future, I would be able to estimate the lifetime costs of breast cancer 
care and explore whether using cost estimates with patient-level routine data would 
change the cost-effectiveness results in the economic evaluation. Also, I conducted the 
complete case analysis using only data from patients for whom all variables involved in 
the analysis were observed. In future study, I could use multiple imputation to impute the 
missing data.  
In addition, using the patient-level I would be able to match patients who were diagnosed 
with the same stage but had different treatment options. As the datasets have been 
linked to ONS Death Register, I could also conduct survival analyses and investigate the 
impact of patient characteristics on survival using regression modelling. This provides 
me an opportunity to compare both cost and survival among patients diagnosed at the 
same stage receiving different treatment, thus to inform the cost-effectiveness analysis 
of stage-specific breast cancer therapies. In Chapter 8, the study population was 
restricted to breast cancer patients diagnosed between 01 January 2014 and 31 
December 2015 and the data was available up to 31 December 2016 so that no patients 
were censored in the current analysis of one-year breast cancer costs. Future research 
188 
 
could take censored data into consideration to predict two-year breast cancer costs, 
using principled methods for censored adjusted analysis (166-168).  
9.6 Concluding comments 
In urban China, risk-based screening for breast cancer is very likely to be cost-effective. 
But in rural China, breast screening among the general population reports uncertain cost-
effectiveness and could potentially harm women’s health due to false positives with the 
current screening tools. In a rural setting with such low breast cancer incidence, priority 
should be given to ensure that symptomatic women have proper access to diagnosis 
and treatment at an early stage as this will lead to mortality reductions without the usual 
screening harms. 
Unselected panel genetic-testing for all breast cancer patients is extremely cost-effective 
compared to the current practice of family-history/clinical-criteria based genetic (BRCA)-
testing for both UK and US health systems. This supports changing the current policy to 
expand genetic-testing to all women with breast cancer.   
Costs of breast cancer care increased with increasing stage of the disease at diagnosis 
in England. Considerable cost savings could be made if breast cancer was detected and 
treated earlier. Variations in breast cancer costs by age andregion raise questions about 
the efficiency and consistency of breast cancer treatment patterns in England.  
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Appendices 
Appendix-1 Relationship between breast cancer FIGO staging and TNM classification 
FIGO Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
  T1 N1mi M0 
IIA T0 N1 M0 
  T1 N1 M0 
  T2 N0 M0 
IIB T2 N1 M0 
  T3 N0 M0 
IIIA T0 N2 M0 
  T1 N2 M0 
  T2 N2 M0 
  T3 N1 M0 
  T3 N2 M0 
IIIB T4 N0 M0 
  T4 N1 M0 
  T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
 
In the TNM staging system for breast cancer, Tumour (T) describes the size of the 
tumour, Node (N) describes whether the cancer has spread to the lymph nodes, and 
Metastasis (M) describes whether the cancer has spread to a different part of the body.  
Tis means ductal carcinoma in situ (DICS).  
T1 means that the tumour is 2 centimetres (cm) across or less. 
T2 means that the tumour is more than 2 centimetres but no more than 5 centimetres 
across. 
T3 means the tumour is bigger than 5 centimetres across. 
T4 is divided into four groups: T4a means the tumour has spread into the chest wall 
(the structures surrounding and protecting the lungs); T4b means the tumour has 
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spread into the skin and the breast might be swollen; T4c means the tumour has 
spread to both the skin and the chest wall; T4d means inflammatory carcinoma – this is 
a cancer in which the overlying skin is red, swollen and painful. 
N0 means there are no cancer cells in any nearby nodes. 
N1 means cancer cells are in the lymph nodes in the armpit but the nodes are not stuck 
to surrounding tissues. 
N2 is divided into 2 groups: N2a means there are cancer cells in the lymph nodes in 
the armpit, which are stuck to each other and to other structures; N2b means there are 
cancer cells in the lymph nodes behind the breast bone (the internal mammary nodes), 
which have been seen on a scan or felt by the doctor. There is no evidence of cancer 
in lymph nodes in the armpit. 
N3 is divided into 3 groups: N3a means there are cancer cells in lymph nodes below 
the collarbone; N3b means there are cancer cells in lymph nodes in the armpit and 
behind the breastbone; N3c means there are cancer cells in lymph nodes above the 
collarbone. 
M0 means that there is no sign that the cancer has spread. 
M1 means the cancer has spread to another part of the body. 
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Appendix-2 Search Strategy – MEDLINE and EMBASE (Ovid: Jan 2013 to Mar 2019) 
 Searches Results - 
MEDLINE 
Results - 
EMBASE 
1 Breast cancer or breast tumor or breast tumour or 
breast neoplasm or mammon cancer or mammo tumor 
or mammo tumour or mammo neoplasm 
219218 510212 
2 exp Breast Neoplasms/ 273043 505250 
3 1 or 2 310539 554987 
4 exp Cost-Benefit Analysis/ 75610 80246 
5 econom* adj3 evaluation* 9869 23978 
6 (cost* adj3 effective*) or (cost* adj3 benefit*) or (cost* 
adj3 utilit*) or willingness to pay or net benefit* 
155879 312712 
7 4 or 5 or 6 158866 322330 
8 3 and 7 3334 8462 
9 Developing Countries.sh,kf. 82257 21 
10 (Africa or Asia or Caribbean or West Indies or South 
America or Latin America or Central 
America).hw,kf,ti,ab,cp. 
225286 330203 
11 (Afghanistan or Albania or Algeria or Angola or Antigua 
or Barbuda or Argentina or Armenia or Armenian or 
Aruba or Azerbaijan or Bahrain or Bangladesh or 
Barbados or Benin or Byelarus or Byelorussian or 
Belarus or Belorussian or Belorussia or Belize or 
Bhutan or Bolivia or Bosnia or Herzegovina or 
Hercegovina or Botswana or Brasil or Brazil or 
Bulgaria or Burkina Faso or Burkina Fasso or Upper 
Volta or Burundi or Urundi or Cambodia or Khmer 
Republic or Kampuchea or Cameroon or Cameroons 
or Cameron or Camerons or Cape Verde or Central 
African Republic or Chad or Chile or China or 
Colombia or Comoros or Comoro Islands or Comores 
or Mayotte or Congo or Zaire or Costa Rica or Cote 
d'Ivoire or Ivory Coast or Croatia or Cuba or Cyprus or 
Czechoslovakia or Czech Republic or Slovakia or 
Slovak Republic or Djibouti or French Somaliland or 
Dominica or Dominican Republic or East Timor or East 
Timur or Timor Leste or Ecuador or Egypt or United 
Arab Republic or El Salvador or Eritrea or Estonia or 
Ethiopia or Fiji or Gabon or Gabonese Republic or 
Gambia or Gaza or Georgia Republic or Georgian 
Republic or Ghana or Gold Coast or Greece or 
Grenada or Guatemala or Guinea or Guam or Guiana 
or Guyana or Haiti or Honduras or Hungary or India or 
Maldives or Indonesia or Iran or Iraq or Isle of Man or 
Jamaica or Jordan or Kazakhstan or Kazakh or Kenya 
or Kiribati or Korea or Kosovo or Kyrgyzstan or 
Kirghizia or Kyrgyz Republic or Kirghiz or Kirgizstan or 
2977827 4106070 
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Lao PDR or Laos or Latvia or Lebanon or Lesotho or 
Basutoland or Liberia or Libya or Lithuania or 
Macedonia or Madagascar or Malagasy Republic or 
Malaysia or Malaya or Malay or Sabah or Sarawak or 
Malawi or Nyasaland or Mali or Malta or Marshall 
Islands or Mauritania or Mauritius or Agalega Islands 
or Mexico or Micronesia or Middle East or Moldova or 
Moldovia or Moldovian or Mongolia or Montenegro or 
Morocco or Ifni or Mozambique or Myanmar or 
Myanma or Burma or Namibia or Nepal or Netherlands 
Antilles or New Caledonia or Nicaragua or Niger or 
Nigeria or Northern Mariana Islands or Oman or 
Muscat or Pakistan or Palau or Palestine or Panama or 
Paraguay or Peru or Philippines or Philipines or 
Phillipines or Phillippines or Poland or Portugal or 
Puerto Rico or Romania or Rumania or Roumania or 
Russia or Russian or Rwanda or Ruanda or Saint Kitts 
or St Kitts or Nevis or Saint Lucia or St Lucia or Saint 
Vincent or St Vincent or Grenadines or Samoa or 
Samoan Islands or Navigator Island or Navigator 
Islands or Sao Tome or Saudi Arabia or Senegal or 
Serbia or Montenegro or Seychelles or Sierra Leone or 
Slovenia or Sri Lanka or Ceylon or Solomon Islands or 
Somalia or South Africa or Sudan or Suriname or 
Surinam or Swaziland or Syria or Tajikistan or 
Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or 
Thailand or Togo or Togolese Republic or Tonga or 
Trinidad or Tobago or Tunisia or Turkey or 
Turkmenistan or Turkmen or Uganda or Ukraine or 
Uruguay or USSR or Soviet Union or Union of Soviet 
Socialist Republics or Uzbekistan or Uzbek or Vanuatu 
or New Hebrides or Venezuela or Vietnam or Viet Nam 
or West Bank or Yemen or Yugoslavia or Zambia or 
Zimbabwe or Rhodesia).hw,kf,ti,ab,cp. 
12 ((developing or less* developed or under developed or 
underdeveloped or middle income or low* income or 
underserved or under served or deprived or poor*) adj 
(countr* or nation? or population? or world)).ti,ab. 
73390 112771 
13 ((developing or less* developed or under developed or 
underdeveloped or middle income or low* income) adj 
(economy or economies)).ti,ab. 
368 621 
14 (low* adj (gdp or gnp or gross domestic or gross 
national)).ti,ab. 
208 329 
15 (low adj3 middle adj3 countr*).ti,ab. 8800 14186 
16 (lmic or lmics or third world or lami countr*).ti,ab. 4844 7444 
17 transitional countr*.ti,ab. 131 217 
18 or/9-17 3104135 4299459 
19 8 and 18 308 989 
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20 Exp Mass Screening/ 119703 224541 
21 Screening.mp. 484160 975880 
22 20 or 21 493005 976626 
23 19 and 22 135 331 
24 Limit 23 to yr="2013-2019" 52 176 
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Appendix-3 Search Strategy – MEDLINE and EMBASE (Ovid: Jan 2015 to Mar 2019) 
 Searches Results - 
MEDLINE 
Results - 
EMBASE 
1 Breast cancer or breast tumor or breast 
tumour or breast neoplasm or mammon 
cancer or mammo tumor or mammo tumour 
or mammo neoplasm 
219218 510212 
2 exp Breast Neoplasms/ 273043 505250 
3 310539 310539 554987 
4 exp Cost-Benefit Analysis/ 75610 80246 
5 econom* adj3 evaluation* 9869 23978 
6 (cost* adj3 effective*) or (cost* adj3 benefit*) 
or (cost* adj3 utilit*) or willingness to pay or 
net benefit* 
155879 312712 
7 4 or 5 or 6 158866 322330 
8 3 and 7 3334 8462 
9 Exp Genetic Testing/ 42137 75324 
10 Genetic testing.mp. 41928 29198 
11 9 or 10 49397 84107 
12 8 and 11 141 321 
13 Exp patients/ 59408 2643369 
14 12 and 13 0 75 
15 limit 12 to yr="2015-2019" 0 26 
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Appendix-4 Summary of crude costs of breast cancer care (GBP in 2016 values) – mean (standard error) 
Cost categories All (n=55,662) Stage I (n=28,232) Stage II (n=24,358) Stage IIIA (n=3,072) 
Diagnosis and procedure costs 3,659 (2,716) 3,366 (2,376) 3,831 (2,966) 4,998 (3,045) 
Chemotherapy costs  837 (2,536) 437 (1,966) 1,141 (2,867) 2,097 (3,480) 
Radiotherapy costs 689 (2,055) 341 (911) 815 (2,300) 2,892 (4,572) 
Endocrine therapy costs 34 (19) 35 (18) 33 (20) 32 (20) 
Targeted therapy costs 782 (2,973) 535 (2,484) 993 (3,317) 1,392 (3,857) 
Total costs 6,002 (6,576) 4,714 (5,078) 6,812 (7,261) 11,412 (8,881) 
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Appendix-5 Results for first-year total costs of breast cancer care of alternative models 
– co-efficient (standard error) 
Variables OLS Log-Normal Log-Gamma 
Stage II 2,002 (79)*** 1,923 (70)*** 2,031 (71)*** 
Stage IIIA 5,995 (159)*** 4,683 (133)*** 6,704 (256)*** 
Age  -160 (4)*** -145 (3)*** -192 (4)*** 
Ethnicity - Asian -391 (227) -319 (176) -345 (201) 
Ethnicity - Black 533 (305) -432 (198)* 379 (300) 
Ethnicity - other 307 (294) 120 (216) 50 (276) 
Charlson score 1 -453 (126)*** -573 (119)*** -624 (110)*** 
Charlson score 2 -1,501 (208)*** -1,759 (213)*** -1,828 (147)*** 
Charlson score 3 -1,856 (288)*** -3,137 (328)*** -3,430 (142)*** 
IMD 2 305 (130)* 373 (108)** 204 (117) 
IMD 3 374 (127)** 353 (106)** 368 (115)** 
IMD 4 443 (125)*** 398 (105)*** 488 (114)*** 
IMD 5 – least deprived 599 (124)*** 601 (104)*** 572 (114)*** 
ER Negative 1,052 (126)*** 543 (89)*** 1,352 (129)*** 
ER Borderline 1,232 (1,519) 213 (835) 2,252 (1,818) 
PR Negative 801 (106)*** 871 (85)*** 873 (102)*** 
PR Borderline 428 (801) 335 (624) -41 (706) 
HER2 Negative -9,072 (112)*** -8,281 (107)*** -8,162 (195)*** 
HER2 Borderline -7,645 (193)*** -6,716 (191)*** -6,927 (244)*** 
Screen-detected -339 (84)*** -69 (71) -155 (76)* 
Region *** *** *** 
Region × Stage *** *** *** 
***p<0.001, **p<0.01, *p<0.05 
 
